• Breast Cancer Screening Utilization and Outcomes in Women with Neurofibromatosis Type 1.
    • Yan K, Gao Y, Heller SL.
    • Clin Breast Cancer. 2023 Feb 12:S1526-8209(23)00035-6. doi: 10.1016/j.clbc.2023.02.005. Epub ahead of print.
    • Factors Influencing Residual Glandular Breast Tissue after Risk-Reducing Mastectomy in Genetically Predisposed Individuals Detected by MRI Mammography.
    • Dietzel F, Kolberg L, Vesper AS, Hoffmann J, Nestle-Krämling C, Zwiefel K, Friebe V, Sawicki LM, Bruckmann NM, Jannusch K, Morawitz J, Antoch G, Fehm TN, Kirchner J, Mohrmann S.
    • Cancers (Basel). 2023 Jan 29;15(3):829. doi: 10.3390/cancers15030829.
    • MR imaging phenotypes and features associated with pathogenic mutation to predict recurrence or metastasis in breast cancer.
    • Shao Z, Yu J, Cheng Y, Ma W, Liu P, Lu H.
    • BMC Cancer. 2023 Jan 27;23(1):97. doi: 10.1186/s12885-023-10555-5.
    • Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2.
    • Yadav S, Boddicker NJ, Na J, Polley EC, Hu C, Hart SN, Gnanaolivu RD, Larson N, Holtegaard S, Huang H, Dunn CA, Teras LR, Patel AV, Lacey JV, Neuhausen SL, Martinez E, Haiman C, Chen F, Ruddy KJ, Olson JE, John EM, Kurian AW, Sandler DP, O'Brien KM, Taylor JA, Weinberg CR, Anton-Culver H, Ziogas A, Zirpoli G, Goldgar DE, Palmer JR, Domchek SM, Weitzel JN, Nathanson KL, Kraft P, Couch FJ.
    • J Clin Oncol. 2023 Jan 9:JCO2201239. doi: 10.1200/JCO.22.01239. Epub ahead of print.
    • Risk Assessment and Pancreatic Cancer: Diagnostic Management and Artificial Intelligence.
    • Granata V, Fusco R, Setola SV, Galdiero R, Maggialetti N, Silvestro L, De Bellis M, Di Girolamo E, Grazzini G, Chiti G, Brunese MC, Belli A, Patrone R, Palaia R, Avallone A, Petrillo A, Izzo F.
    • Cancers (Basel). 2023 Jan 5;15(2):351. doi: 10.3390/cancers15020351.
    • Variations in Practice and Geographic Disparities Between Dedicated Multidisciplinary Clinics for BRCA1/BRCA2 Mutation Carriers in Israel.
    • Hermann N, Mor P, Kaidar-Person O, Bernstein-Molho R, Brodsky M, Madorsky Feldman D, Flugelman AA, Aboody Nevo H, Meshoulam Avital D, Sklair-Levy M, Friedman E, Allweis TM.
    • Isr Med Assoc J. 2023 Jan;25(1):18-22.
    • Pregnancy-Associated Breast Cancer in BRCA1/2 Carriers: Is Intensified Breast Ultrasound Surveillance Warranted?
    • Fruchtman-Brot H, Mango VL.
    • Acad Radiol. 2022 Dec 19:S1076-6332(22)00595-5. doi: 10.1016/j.acra.2022.11.004. Epub ahead of print.
    • Commentary
    • Impact of the 2018 ACR Supplemental Screening Recommendations on MRI Eligibility in Breast Cancer Survivors.
    • Lieberenz J, Levy M, Alvarado R, Paul S, Cobleigh M, Usha L, Stempel L.
    • J Am Coll Radiol. 2022 Dec 11:S1546-1440(22)00895-X. doi: 10.1016/j.jacr.2022.11.010. Epub ahead of print.
    • Is Sentinel Lymph Node Biopsy Necessary in Patients who Undergo Prophylactic Mastectomy?
    • Madan V, Mamounas EP.
    • Clin Breast Cancer. 2022 Dec 7:S1526-8209(22)00271-3. doi: 10.1016/j.clbc.2022.12.003. Epub ahead of print.
    • Halo Diagnostics, Ikonopedia Partner to Provide Genetic Testing for Breast Cancer.
    • [No author given]
    • Precision Oncology News. 2022 Nov 28.
    • UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2.
    • Hanson H, Kulkarni A, Loong L, Kavanaugh G, Torr B, Allen S, Ahmed M, Antoniou AC, Cleaver R, Dabir T, Evans DG, Golightly E, Jewell R, Kohut K, Manchanda R, Murray A, Murray J, Ong KR, Rosenthal AN, Woodward ER, Eccles DM, Turnbull C, Tischkowitz M; Consensus meeting attendees, Lalloo F.
    • J Med Genet. 2022 Nov 21:jmg-2022-108898. doi: 10.1136/jmg-2022-108898. Epub ahead of print.
    • Feasibility Study and Clinical Impact of Incorporating Breast Tissue Density in High-Risk Breast Cancer Screening Assessment.
    • Rusnak A, Morrison S, Smith E, Hastings V, Anderson K, Aldridge C, Zelenietz S, Reddick K, Regnier S, Alie E, Islam N, Fasih R, Peddle S, Cordeiro E, Tomiak E, Seely JM.
    • Curr Oncol. 2022 Nov 15;29(11):8742-8750. doi: 10.3390/curroncol29110688.
    • A genome-wide association study of mammographic texture variation.
    • Liu Y, Chen H, Heine J, Lindstrom S, Turman C, Warner ET, Winham SJ, Vachon CM, Tamimi RM, Kraft P, Jiang X.
    • Breast Cancer Res. 2022 Nov 7;24(1):76. doi: 10.1186/s13058-022-01570-8.
    • Use of Breast Cancer Risk Factors to Identify Risk-Adapted Starting Age of Screening in China.
    • Zheng Y, Dong X, Li J, Qin C, Xu Y, Wang F, Cao W, Xia C, Yu Y, Zhao L, Wu Z, Luo Z, Chen W, Li N, He J.
    • JAMA Netw Open. 2022 Nov 1;5(11):e2241441. doi: 10.1001/jamanetworkopen.2022.41441.

    Related:

    •• Commentary:

    Risk-Based Approaches to Breast Cancer Screening in China.

    • Ductal Carcinoma In Situ (DCIS) Diagnosed by MRI-Guided Biopsy among BRCA1/BRCA2 Mutation Carriers.
    • Faermann R, Friedman E, Kaidar-Person O, Weidenfeld J, Brodsky M, Shalmon A, Neiman OH, Gotlieb M, Yagil Y, Samoocha D, Madorsky Feldman D, Sklair-Levy M.
    • Breast J. 2022 Oct 27. doi: 10.1155/2022/4317693. Online ahead of print.
    • Relationship between Baseline [18F]FDG PET/CT Semiquantitative Parameters and BRCA Mutational Status and Their Prognostic Role in Patients with Invasive Ductal Breast Carcinoma.
    • Dondi F, Albano D, Bellini P, Camoni L, Treglia G, Bertagna F.
    • Tomography. 2022 Oct 27;8(6):2662-2675. doi: 10.3390/tomography8060222.
    • Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
    • Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M, Ledermann JA, Loibl S, Phillips KA, Shimon P; ESMO Guidelines Committee.
    • Ann Oncol. 2022 Oct 19:S0923-7534(22)04193-X. doi: 10.1016/j.annonc.2022.10.004. Epub ahead of print.
    • Breast cancer incidence among women with a family history of breast cancer by relative's age at diagnosis.
    • Durham DD, Abraham LA, Roberts MC, Khan CP, Smith RA, Kerlikowske K, Miglioretti DL.
    • Cancer. 2022 Oct 19. doi: 10.1002/cncr.34365. Epub ahead of print.

    Related:

    •• Commentary:

    What if the age at which a woman started regular mammographic screening depended on her risk, not age?

    •• Press release: Study finds earlier mammograms for women with family history of breast cancer may not be needed. (UC Davis Health | News)

    •• Research news: Earlier mammograms for women with family history of breast cancer may not be needed. (ScienceDaily)

    •• Research news: Earlier Mammograms Based on Family Breast Cancer History May Not Be Necessary. (Inside Precision Medicine)

    • Polygenic Risk Scores Could Refine Breast Cancer Screening Recommendations.
    • Curtin C.
    • Precision Oncology News. 2022 Oct 17.
    • Research news
    • Tattoo Pigment in an Intramammary Lymph Node Mimicking Breast Malignancy.
    • Jung J, Peters G, Donovan S, Peters G.
    • Cureus. 2022 Oct 15;14(10):e30336. doi: 10.7759/cureus.30336.
    • Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.
    • Powell CB, Laurent C, Garcia C, Hoodfar E, Karlea A, Kobelka C, Lee J, Roh J, Kushi LH.
    • Gynecol Oncol. 2022 Oct 8:S0090-8258(22)01857-1. doi: 10.1016/j.ygyno.2022.10.001. Epub ahead of print.
    • Incidence of Occult Breast Cancer in Carriers of BRCA1/2 or Other High-Penetrance Pathogenic Variants Undergoing Prophylactic Mastectomy: When is Sentinel Lymph Node Biopsy Indicated?
    • Wong SM, Ferroum A, Apostolova C, Alhassan B, Prakash I, Basik M, Boileau JF, Meterissian S, Aleynikova O, Wong N, Foulkes WD.
    • Ann Surg Oncol. 2022 Oct;29(11):6660-6668. doi: 10.1245/s10434-022-11916-3. Epub 2022 May 26.
    • Use of breast surveillance between women with pathogenic variants and variants of uncertain significance in breast cancer susceptibility genes.
    • Makhnoon S, Chen M, Levin B, Ensinger M, Mattie KD, Grana G, Shete S, Arun BK, Peterson SK.
    • Cancer. 2022 Oct;128(20):3709-3717. doi: 10.1002/cncr.34429. Epub 2022 Aug 23.
    • Hereditary Ovarian Cancer: Towards a Cost-Effective Prevention Strategy.
    • Ghose A, Bolina A, Mahajan I, Raza SA, Clarke M, Pal A, Sanchez E, Rallis KS, Boussios S.
    • Int J Environ Res Public Health. 2022 Sep 23;19(19):12057. doi: 10.3390/ijerph191912057.
    • Controversies and Open Questions in Management of Cancer-Free Carriers of Germline Pathogenic Variants in BRCA1/BRCA2.
    • Bernstein-Molho R, Friedman E, Evron E.
    • Cancers (Basel). 2022 Sep 22;14(19):4592. doi: 10.3390/cancers14194592.
    • Detection of Breast Cancer Lump and BRCA1/2 Genetic Mutation under Deep Learning.
    • Miao Y, Tang S.
    • Comput Intell Neurosci. 2022 Sep 19;2022:9591781. doi: 10.1155/2022/9591781.
    • Prophylactic mastectomy and occult malignancy: Surgical and imaging considerations.
    • Thompson JL, Sinco BR, McCaffrey RL, Chang AE, Sabel MS, Dossett LA, Hughes TM, Jeruss JS.
    • J Surg Oncol. 2022 Sep 7. doi: 10.1002/jso.27088. Epub ahead of print.
    • Breast cancer screening in average and high-risk women.
    • Rahman WT, Helvie MA.
    • Best Pract Res Clin Obstet Gynaecol. 2022 Sep;83:3-14. doi: 10.1016/j.bpobgyn.2021.11.007. Epub 2021 Nov 19.
    • Review
    • Breast cancer risk reduction: who, why, and what?
    • Bozzuto LM.
    • Best Pract Res Clin Obstet Gynaecol. 2022 Sep;83:36-45. doi: 10.1016/j.bpobgyn.2021.11.012. Epub 2021 Dec 8.
    • Review
    • Background Parenchymal Enhancement at Postoperative Surveillance Breast MRI: Association with Future Second Breast Cancer Risk.
    • Lee SH, Jang MJ, Yoen H, Lee Y, Kim YS, Park AR, Ha SM, Kim SY, Chang JM, Cho N, Moon WK.
    • Radiology. 2022 Aug 30:220440. doi: 10.1148/radiol.220440. Epub ahead of print.

    Related:

    Commentary:

    Background Parenchymal Enhancement at Breast MRI: More Is Not Better.

    • Reaching beyond family history as inclusion criteria for pancreatic cancer surveillance in high-risk populations.
    • Wang L, Domchek SM, Kochman ML, Katona BW.
    • Genes Cancer. 2022 Aug 29;13:49-51. doi: 10.18632/genesandcancer.223.
    • Current Screening Strategies for Pancreatic Cancer.
    • Vanek P, Urban O, Zoundjiekpon V, Falt P.
    • Biomedicines. 2022 Aug 23;10(9):2056. doi: 10.3390/biomedicines10092056.
    • High Risk Breast Cancer Screening is a Double Edged Sword: A Qualitative Study of Patient Perspectives on the Ontario High Risk Breast Cancer Screening Program.
    • Deng SX, Castelo M, Reel E, Naganathan G, Eisen A, Muradali D, Grunfeld E, Scheer AS.
    • Clin Breast Cancer. 2022 Aug 19:S1526-8209(22)00183-5. doi: 10.1016/j.clbc.2022.08.004. Epub ahead of print.
    • Axillary Lymphadenopathy associated with COVID-19 vaccination: updates and recommendations.
    • Schwaner SL.
    • J Radiol Nurs. 2022 Aug 19. doi: 10.1016/j.jradnu.2022.08.006. Epub ahead of print.
    • BI-RADS-0 screening mammography: Risk factors that prevent or delay follow-up time to diagnostic evaluation.
    • Platt S, Montgomery GH, Schnur JH, Margolies L.
    • J Am Coll Radiol. 2022 Aug 16:S1546-1440(22)00576-2. doi: 10.1016/j.jacr.2022.07.006. Epub ahead of print.

    Related:

    Commentary:

    Reducing Disparities in Timely Follow-Up after an Abnormal Screening Mammogram.

    • Does receiving high or low breast cancer risk estimates produce a reduction in subsequent breast cancer screening attendance? Cohort study.
    • French DP, McWilliams L, Howell A, Evans DG.
    • Breast. 2022 Aug;64:47-49. doi: 10.1016/j.breast.2022.05.001. Epub 2022 May 9.
    • Global guidelines for breast cancer screening: A systematic review.
    • Ren W, Chen M, Qiao Y, Zhao F.
    • Breast. 2022 Aug;64:85-99. doi: 10.1016/j.breast.2022.04.003. Epub 2022 Apr 19.
    • Surveillance mammography after treatment for male breast cancer.
    • Yadav S, Sangaralingham L, Payne SR, Giridhar KV, Hieken TJ, Boughey JC, Mutter RW, Hawse JR, Jimenez RE, Freedman RA, Khanani S, Couch FJ, Vachon C, Shah N, Leon-Ferre RA, Ruddy KJ.
    • Breast Cancer Res Treat. 2022 Aug;194(3):693-698. doi: 10.1007/s10549-022-06645-w. Epub 2022 Jun 17.
    • Factors Associated with Mammography Screening Choices by Women Aged 40-49 at Average Risk.
    • Guan Y, Haardörfer R, McBride CM, Lipscomb J, Escoffery C.
    • J Womens Health (Larchmt). 2022 Aug;31(8):1120-1126. doi: 10.1089/jwh.2021.0232. Epub 2022 Feb 15.
    • Risk-reducing mastectomy for women with hereditary breast and ovarian cancer (HBOC): analytical results of data from the Japanese Organization of HBOC.
    • Ohsumi S, Nakamura S, Miyata H, Watanabe C, Den H, Arai M.
    • Jpn J Clin Oncol. 2022 Jul 30:hyac120. doi: 10.1093/jjco/hyac120. Epub ahead of print.
    • An Overview on Radiation Sensitivity in Hereditary Breast and Ovarian Cancer Syndrome.
    • Gonçalves D, Pires AS, Marques IA, Gomes I, Sousa G, Botelho MF, Abrantes AM.
    • Cancers (Basel). 2022 Jul 2;14(13):3254. doi: 10.3390/cancers14133254.
    • Autres approches en dépistage du cancer du sein [Other approaches in breast cancer screening].
    • Veron L, Wehrer D, Caron O, Balleyguier C, Delaloge S.
    • Bull Cancer. 2022 Jul-Aug;109(7-8):786-794. French. doi: 10.1016/j.bulcan.2022.02.006. Epub 2022 May 5.
    • Review. [Article in French]
    • Survival of BRCA1/BRCA2-associated pT1 breast cancer patients, a cohort study.
    • van Barele M, Rieborn A, Heemskerk-Gerritsen BAM, Obdeijn IM, Koppert LB, Loo CE, Tollenaar RAEM, Ausems MGEM, van de Beek I, Berger LPV, de Boer M, van Hest LP, Kets CM, Rookus M; Hebon, Schmidt MK, Jager A, Hooning MJ.
    • Breast Cancer Res Treat. 2022 Jul;194(1):159-170. doi: 10.1007/s10549-022-06608-1. Epub 2022 May 4.
    • Breast cancer risk stratification in women of screening age: Incremental effects of adding mammographic density, polygenic risk, and a gene panel.
    • Evans DGR, van Veen EM, Harkness EF, Brentnall AR, Astley SM, Byers H, Woodward ER, Sampson S, Southworth J, Howell SJ, Maxwell AJ, Newman WG, Cuzick J, Howell A.
    • Genet Med. 2022 Jul;24(7):1485-1494. doi: 10.1016/j.gim.2022.03.009. Epub 2022 Apr 15.
    • Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.
    • Liberto JM, Chen SY, Shih IM, Wang TH, Wang TL, Pisanic TR 2nd.
    • Cancers (Basel). 2022 Jun 11;14(12):2885. doi: 10.3390/cancers14122885.
    • Genetic Aspects of Mammographic Density Measures Associated with Breast Cancer Risk.
    • Li S, Nguyen TL, Nguyen-Dumont T, Dowty JG, Dite GS, Ye Z, Trinh HN, Evans CF, Tan M, Sung J, Jenkins MA, Giles GG, Hopper JL, Southey MC.
    • Cancers (Basel). 2022 Jun 2;14(11):2767. doi: 10.3390/cancers14112767.
    • The yield and effectiveness of breast cancer surveillance in women with PTEN Hamartoma Tumor Syndrome.
    • Hoxhaj A, Drissen MMCM, Vos JR, Bult P, Mann RM, Hoogerbrugge N.
    • Cancer. 2022 Jun 1. doi: 10.1002/cncr.34326. Epub ahead of print
    • Cancer genetics and breast cancer.
    • Huber-Keener KJ.
    • Best Pract Res Clin Obstet Gynaecol. 2022 Jun;82:3-11. doi: 10.1016/j.bpobgyn.2022.01.007. Epub 2022 Jan 31.
    • Review
    • CT-Based Radiomics and Deep Learning for BRCA Mutation and Progression-Free Survival Prediction in Ovarian Cancer Using a Multicentric Dataset.
    • Avesani G, Tran HE, Cammarata G, Botta F, Raimondi S, Russo L, Persiani S, Bonatti M, Tagliaferri T, Dolciami M, Celli V, Boldrini L, Lenkowicz J, Pricolo P, Tomao F, Rizzo SMR, Colombo N, Manganaro L, Fagotti A, Scambia G, Gui B, Manfredi R.
    • Cancers (Basel). 2022 May 31;14(11):2739. doi: 10.3390/cancers14112739.
    • Breast cancer risk for transgender men with inherited mutations.
    • [No author given]
    • FORCE. XRAY. 2022 May 19.

    Related:

    Commentary:

    BRCA Mutations and the Implications in Transgender Individuals Undergoing Top Surgery: An Operative Dilemma.

    • Pregnancy Associated Breast Cancer Among Israeli BRCA1/BRCA2 Carriers in a High-Risk Clinic.
    • Faermann R, Friedman E, Kaidar-Person O, Brodsky M, Neiman OH, Shalmon A, Gotlieb M, Yagil Y, Samocha D, Feldman DM, Weidenfeld J, Sklair-Levy M.
    • Acad Radiol. 2022 May 5:S1076-6332(22)00207-0. doi: 10.1016/j.acra.2022.03.030. Epub ahead of print.
    • Screening and risk reducing surgery for endometrial or ovarian cancers in Lynch syndrome: a systematic review.
    • Lim N, Hickey M, Young GP, Macrae FA, Kelly C.
    • Int J Gynecol Cancer. 2022 May 3;32(5):646-655. doi: 10.1136/ijgc-2021-003132.
    • MRI Screening of BRCA Mutation Carriers: Comparison of Standard Protocol and Abbreviated Protocols With and Without T2-Weighted Images.
    • Naranjo ID, Sogani J, Saccarelli C, Horvat JV, Sevilimedu V, Hughes MC, Gullo RL, Jochelson MS, Reiner J, Pinker K.
    • AJR Am J Roentgenol. 2022 May;218(5):810-820. doi: 10.2214/AJR.21.27022. Epub 2021 Dec 22.

    Related:

    Commentary:

    Abbreviated Breast MRI-Good but Not All the Same.

    Author Video: MRI Screening of BRCA Mutation Carriers. (YouTube / AJR Radiology)

    • ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations.
    • Sawhney MS, Calderwood AH, Thosani NC, Rebbeck TR, Wani S, Canto MI, Fishman DS, Golan T, Hidalgo M, Kwon RS, Riegert-Johnson DL, Sahani DV, Stoffel EM, Vollmer CM Jr, Qumseya BJ; Prepared by: ASGE STANDARDS OF PRACTICE COMMITTEE.
    • Gastrointest Endosc. 2022 May;95(5):817-826. doi: 10.1016/j.gie.2021.12.001. Epub 2022 Feb 16.

    Related:

    Guideline:

    American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review of evidence.

    Video: 2022 May Author Interview-Bashar Qumseya, Mandeep S. Sawhney, and Audrey H. Calderwood. (Author Interview Series / YouTube)

    News: ASGE Expands BRCA Screening for Pancreatic Cancer. (Inside Precision Medicine)

    • Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.
    • Lowry KP, Geuzinge HA, Stout NK, Alagoz O, Hampton J, Kerlikowske K, de Koning HJ, Miglioretti DL, van Ravesteyn NT, Schechter C, Sprague BL, Tosteson ANA, Trentham-Dietz A, Weaver D, Yaffe MJ, Yeh JM, Couch FJ, Hu C, Kraft P, Polley EC, Mandelblatt JS, Kurian AW, Robson ME; Breast Working Group of the Cancer Intervention and Surveillance Modeling Network (CISNET), in collaboration with the Breast Cancer Surveillance Consortium (BCSC), and the Cancer Risk Estimates Related to Susceptibility (CARRIERS) Consortium.
    • JAMA Oncol. 2022 Apr 1;8(4):587-596. doi: 10.1001/jamaoncol.2021.6204.

    Related:

    Research news: Breast Cancer Screening with MRI Recommended for Women with Pathogenic Variants. (Inside Precision Medicine)

    Research news: MRI Could Reduce Breast Cancer Deaths in Women at High Risk. (Medscape)

    • Effective Surveillance of High-Risk Women.
    • Lotz M, Ghebremichael M, Chervinsky K, Zorc T, Brenner C, Bousvaros G, Pories SE.
    • Clin Breast Cancer. 2022 Apr;22(3):e263-e269. doi: 10.1016/j.clbc.2021.07.014. Epub 2021 Jul 27.
    • Attitude towards hereditary cancer risk management among women with cancer in Taiwan.
    • Fang SY, Hsieh LL, Hung CF, Hung FH, Peng HP, Yang AS, Wang YA.
    • Support Care Cancer. 2022 Apr;30(4):3625-3632. doi: 10.1007/s00520-021-06742-4. Epub 2022 Jan 14.
    • Habitat Analysis of Breast Cancer-Enhanced MRI Reflects BRCA1 Mutation Determined by Immunohistochemistry.
    • Du T, Zhao H.
    • Biomed Res Int. 2022 Mar 30;2022:9623173. doi: 10.1155/2022/9623173.
    • The Breast Cancer Screening and Timing of Breast MRI-Experience in a Genetic High-Risk Screening Clinic in a Comprehensive Cancer Center.
    • Wang X, Chang MD, Lee MC, Niell BL.
    • Curr Oncol. 2022 Mar 19;29(3):2119-2131. doi: 10.3390/curroncol29030171.
    • Axillary lymphadenopathy in a high-risk breast screening patient following the COVID-19 vaccine: a diagnostic conundrum.
    • Musaddaq B, Brown A, Dluzewski S, Marafioti T, Malhotra A.
    • BJR Case Rep. 2022 Mar 9;7(6):20210063. doi: 10.1259/bjrcr.20210063.
    • Clinician-Reported Impact of Germline Multigene Panel Testing on Cancer Risk Management Recommendations.
    • Horton C, Blanco K, Lo MT, Speare V, LaDuca H, Dolinsky JS, Kurian AW.
    • JNCI Cancer Spectr. 2022 Mar 2;6(2):pkac002. doi: 10.1093/jncics/pkac002.
    • Breast cancer risk evaluation for the primary care physician.
    • Klassen CL, Gilman E, Kaur A, Lester SP, Pruthi S.
    • Cleve Clin J Med. 2022 Mar 1;89(3):139-146. doi: 10.3949/ccjm.89a.21023.
    • The current status of risk-stratified breast screening.
    • Clift AK, Dodwell D, Lord S, Petrou S, Brady SM, Collins GS, Hippisley-Cox J.
    • Br J Cancer. 2022 Mar;126(4):533-550. doi: 10.1038/s41416-021-01550-3. Epub 2021 Oct 26.
    • Lapses in breast cancer screening for highly penetrant mutation carriers during pregnancy and lactation.
    • Chichura A, Hunt J, Lang J, Pederson H.
    • J Surg Oncol. 2022 Mar;125(4):589-595. doi: 10.1002/jso.26761. Epub 2021 Dec 2.
    • DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy.
    • Nguyen NT, Pacelli A, Nader M, Kossatz S.
    • Cancers (Basel). 2022 Feb 23;14(5):1129. doi: 10.3390/cancers14051129.
    • Breast Cancer Screening with MRI Recommended for Women with Pathogenic Variants.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Feb 23.

    Related:

    Original research:

    Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.

    • Missed Breast Cancers on MRI in High-Risk Patients: A Retrospective Case-Control Study.
    • Bilocq-Lacoste J, Ferre R, Kuling G, Martel AL, Tyrrell PN, Li S, Wang G, Curpen B.
    • Tomography. 2022 Feb 2;8(1):329-340. doi: 10.3390/tomography8010027.
    • Family History of Breast Cancer and Mammographic Breast Density in Premenopausal Women.
    • Han Y, Moore JX, Colditz GA, Toriola AT.
    • JAMA Netw Open. 2022 Feb 1;5(2):e2148983. doi: 10.1001/jamanetworkopen.2021.48983.

    Related:

    Research news: Breast Density Linked to Familial Breast Cancer Risk. (Medscape)

    • Breast cancer risk in BRCA mutation carriers after diagnosis of epithelial ovarian cancer is lower than in carriers without ovarian cancer.
    • Nañez A, Stram DA, Bethan Powell C, Garcia C.
    • Gynecol Oncol Rep. 2021 Dec 4 [eCollection 2022 Feb];39:100899. doi: 10.1016/j.gore.2021.100899.
    • [SCREENING WOMEN AT HIGH RISK FOR BREAST CANCER - BRCA AND BEYOND].
    • Hermann N, Westergard S, McCready DR.
    • Harefuah. 2022 Feb;161(2):95-100. Hebrew.
    • [Article in Hebrew]
    • Development and pilot testing of an online decision aid for women considering risk-stratified breast screening.
    • Lippey J, Keogh L, Campbell I, Mann GB, Forrest L.
    • J Community Genet. 2022 Feb;13(1):137-141. doi: 10.1007/s12687-021-00571-y. Epub 2022 Jan 21.
    • Malignant prediction of incidental findings using ring-type dedicated breast positron emission tomography.
    • Sasada S, Masumoto N, Emi A, Kadoya T, Okada M.
    • Sci Rep. 2022 Jan 21;12(1):1144. doi: 10.1038/s41598-022-05166-2.
    • Cost-Effectiveness Analysis of Imaging Modalities for Breast Cancer Surveillance Among BRCA1/2 Mutation Carriers: A Systematic Review.
    • Li J, Jia Z, Zhang M, Liu G, Xing Z, Wang X, Huang X, Feng K, Wu J, Wang W, Wang J, Liu J, Wang X.
    • Front Oncol. 2022 Jan 10;11:763161. doi: 10.3389/fonc.2021.763161.
    • BRCA Mutations and the Implications in Transgender Individuals Undergoing Top Surgery: An Operative Dilemma.
    • Jaber C, Ralph O, Hamidian Jahromi A.
    • Plast Reconstr Surg Glob Open. 2022 Jan 10;10(1):e4012. doi: 10.1097/GOX.0000000000004012.

    Related:

    Research news: Breast cancer risk for transgender men with inherited mutations. (FORCE. XRAY)

    • Non-BRCA Early-Onset Breast Cancer in Young Women.
    • Gao Y, Samreen N, Heller SL.
    • Radiographics. 2022 Jan-Feb;42(1):5-22. doi: 10.1148/rg.210109.
    • Review

    Related:

    Commentary:

    Invited Commentary: The Challenges of Early-Onset Breast Cancer.

    • The Value of Tyrer-Cuzick Versus Gail Risk Modeling in Predicting Benefit from Screening MRI in Breast Cancer.
    • Sevdalis A, Deng X, Bandyopadhyay D, McGuire KP.
    • Eur J Breast Health. 2021 Dec 30 [eCollection 2022 Jan];18(1):79-84. doi: 10.4274/ejbh.galenos.2021.2021-8-2.
    • Comparing breast cancer imaging characteristics of CHEK2 with BRCA1 and BRCA2 gene mutation carriers.
    • Ghunaim H, Laenen A, De Keyzer F, Soens J, Keupers M, Postema S, Neven P, Van Ongeval C.
    • Eur J Radiol. 2022 Jan;146:110074. doi: 10.1016/j.ejrad.2021.110074. Epub 2021 Nov 26.
    • Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.
    • John CS, Fong A, Alban R, Gillen J, Moore KM, Walsh CS, Li AJ, Rimel BJ, Amersi F, Cass I.
    • Gynecol Oncol. 2022 Jan;164(1):202-207. doi: 10.1016/j.ygyno.2021.10.077. Epub 2021 Nov 30.
    • Genetic Counseling, Screening and Risk-Reducing Surgery in Patients with Primary Breast Cancer and Germline BRCA Mutations: Unmet Needs in Low- and Middle-Income Countries.
    • Moukadem HA, Al Masry A, Atwani RW, Kreidieh F, Khalil LE, Saroufim R, Daouk S, Dalle IA, El Saghir NS.
    • Eur J Breast Health. 2021 Dec 30;18(1):16-20. doi: 10.4274/ejbh.galenos.2021.2021-5-1.
    • Inter- and intra-observer agreement on evaluating the presence of residual glandular tissue with magnetic resonance tomography following prophylactic mastectomy.
    • Skoglund MA, Andersson MN, Björkgren A, Tolocka E, Sund M, Wiberg R.
    • Acta Radiol. 2021 Dec 1:2841851211058929. doi: 10.1177/02841851211058929. Epub ahead of print.
    • Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe.
    • Marmolejo DH, Wong MYZ, Bajalica-Lagercrantz S, Tischkowitz M, Balmaña J; extended ERN-GENTURIS Thematic Group 3.
    • Eur J Med Genet. 2021 Dec;64(12):104350. doi: 10.1016/j.ejmg.2021.104350. Epub 2021 Oct 1.
    • Review
    • Impact du cycle menstruel sur la qualité de l’interprétation du résultat de l’IRM dans le suivi des femmes à risque génétique de cancer du sein [Impact of the menstrual cycle on the quality of interpretation of the MRI result in the follow-up of women at genetic risk for breast].
    • de Kermadec E, Thomassin I, Daraï E, Kolanska K, Chabbert-Buffet N.
    • Gynecol Obstet Fertil Senol. 2021 Dec;49(12):923-929. French. doi: 10.1016/j.gofs.2021.03.024. Epub 2021 Mar 24.
    • [Article in French]
    • Utilization of breast cancer risk prediction models by cancer genetic counselors in clinical practice predominantly in the United States.
    • Park MS, Weissman SM, Postula KJV, Williams CS, Mauer CB, O'Neill SM.
    • J Genet Couns. 2021 Dec;30(6):1737-1747. doi: 10.1002/jgc4.1442. Epub 2021 Jun 2.
    • UK Women's Views of the Concepts of Personalised Breast Cancer Risk Assessment and Risk-Stratified Breast Screening: A Qualitative Interview Study.
    • Kelley-Jones C, Scott S, Waller J.
    • Cancers (Basel). 2021 Nov 19;13(22):5813. doi: 10.3390/cancers13225813.
    • The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance.
    • Grandi G, Fiocchi F, Cortesi L, Toss A, Boselli F, Sammarini M, Sighinolfi G, Facchinetti F.
    • Menopause. 2021 Nov 1;29(1):63-72. doi: 10.1097/GME.0000000000001883.
    • Breast cancer screening for women at high risk: review of current guidelines from leading specialty societies.
    • Onishi N, Kataoka M.
    • Breast Cancer. 2021 Nov;28(6):1195-1211. doi: 10.1007/s12282-020-01157-1. Epub 2020 Sep 21.
    • Review
    • Four magnetic resonance imaging surveillance-detected breast cancer cases in cancer-free BRCA1/2 mutation carriers.
    • Takaoka M, Ohsumi S, Miyoshi Y, Takahashi M, Takashima S, Aogi K, Shimizu T, Teramoto N, Yamamoto Y, Okamura M.
    • Surg Case Rep. 2021 Oct 21;7(1):228. doi: 10.1186/s40792-021-01313-5.
    • Disparities between Uptake of Germline BRCA1/2 Gene Tests and Implementation of Post-test Management Strategies in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients.
    • Hur YM, Mun J, Kim MK, Lee M, Kim YH, Kim SC.
    • J Korean Med Sci. 2021 Oct 4;36(38):e241. doi: 10.3346/jkms.2021.36.e241.
    • The Effect of Supplemental Imaging on Interval Cancer Rates in Mammography Screening: Systematic Review.
    • Zeng A, Brennan ME, Young S, Mathieu E, Houssami N.
    • Clin Breast Cancer. 2021 Oct 2:S1526-8209(21)00290-1. doi: 10.1016/j.clbc.2021.09.011. Epub ahead of print.
    • Review
    • Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes.
    • Makhnoon S, Tran G, Levin B, Mattie KD, Dreyer B, Volk RJ, Grana G, Arun BK, Peterson SK.
    • Cancer. 2021 Oct 1;127(19):3605-3613. doi: 10.1002/cncr.33668. Epub 2021 Jun 22.
    • Ovarian cancer surveillance in the clinical follow up of women with known BRCA1 or BRCA2 pathogenic variants in a large health care system.
    • Nañez A, Stram DA, Garcia C, Powell CB.
    • Gynecol Oncol. 2021 Oct;163(1):134-141. doi: 10.1016/j.ygyno.2021.07.034. Epub 2021 Jul 27.
    • Germline Genetic Testing for Women With Breast Cancer: Shifting the Paradigm From Whom to Test to Whom NOT to Test.
    • Tung N, Desai N.
    • J Clin Oncol. 2021 Sep 7:JCO2101761. doi: 10.1200/JCO.21.01761. Epub ahead of print.

    Related:

    Original research:

    Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.

    Original research:

    Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.

    • Quantification of dynamic contrast-enhanced ultrasound (CEUS) in non-cystic breast lesions using external perfusion software.
    • Jung EM, Jung F, Stroszczynski C, Wiesinger I.
    • Sci Rep. 2021 Sep 3;11(1):17677. doi: 10.1038/s41598-021-96137-6.
    • Ultrasound Imaging Morphology is Associated with Biological Behavior in Invasive Ductal Carcinoma of the Breast.
    • Vijayaraghavan GR, Kona M, Maheswaran A, Kandil DH, Toke MK, Vedantham S.
    • J Clin Imaging Sci. 2021 Sep 2;11:48. doi: 10.25259/JCIS_60_2021.
    • Association of Population Screening for Breast Cancer Risk With Use of Mammography Among Women in Medically Underserved Racial and Ethnic Minority Groups.
    • Schwartz C, Chukwudozie IB, Tejeda S, Vijayasiri G, Abraham I, Remo M, Shah HA, Rojas M, Carillo A, Moreno L, Warnecke RB, Hoskins KF.
    • JAMA Netw Open. 2021 Sep 1;4(9):e2123751. doi: 10.1001/jamanetworkopen.2021.23751.

    Related:

    Commentary:

    Practice-Changing Opportunity to Reduce Disparities in Screening Mammography-Implementation of Risk Assessment in Primary Care.

    • COVID-19 Vaccination Induced Lymphadenopathy in a Specialized Breast Imaging Clinic in Israel: Analysis of 163 cases.
    • Faermann R, Nissan N, Halshtok-Neiman O, Shalmon A, Gotlieb M, Yagil Y, Samoocha D, Friedman E, Sklair-Levy M.
    • Acad Radiol. 2021 Sep;28(9):1191-1197. doi: 10.1016/j.acra.2021.06.003. Epub 2021 Jun 10.

    Related:

    Commentary:

    Managing the Risk of Delayed Breast Cancer Screening Versus COVID-19 Vaccination Associated Axillary Lymphadenopathy.

    • Surgical Management of Hereditary Breast Cancer.
    • Berger ER, Golshan M.
    • Genes (Basel). 2021 Aug 31;12(9):1371. doi: 10.3390/genes12091371.
    • Editorial: HBOC and high-risk screening: up-to-date.
    • Kataoka M.
    • Breast Cancer. 2021 Aug 23. doi: 10.1007/s12282-021-01284-3. Epub ahead of print.
    • The value of clinical breast examination in a breast cancer surveillance program for women with germline BRCA1 or BRCA2 mutations.
    • Hettipathirana T, Macdonald C, Xie J, Moodie K, Michael C, Phillips KA.
    • Med J Aust. 2021 Aug 21. doi: 10.5694/mja2.51226. Epub ahead of print.
    • Breast imaging screening in a BRCA1-mutated lactating patient: A potential pitfall mimicking malignancy.
    • Casinelli A, Malavolta G, Caruso G, Capri O, Ballesio L.
    • Radiol Case Rep. 2021 Aug 14;16(10):3104-3108. doi: 10.1016/j.radcr.2021.07.019.
    • Dealing with cancer screening in the COVID-19 era.
    • Fagundes TP, Albuquerque RM, Miranda DLP, Landeiro LCG, Ayres GSF, Correia CCE, Nogueira-Rodrigues A.
    • Rev Assoc Med Bras (1992). 2021 Aug 13;67Suppl 1(Suppl 1):86-90. doi: 10.1590/1806-9282.67.Suppl1.20200889.
    • Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
    • Tischkowitz M, Balmaña J, Foulkes WD, James P, Ngeow J, Schmutzler R, Voian N, Wick MJ, Stewart DR, Pal T; ACMG Professional Practice and Guidelines Committee.
    • Genet Med. 2021 Aug;23(8):1416-1423. doi: 10.1038/s41436-021-01151-8. Epub 2021 May 11.
    • Guidelines
    • Cost-Sharing and Out-of-Pocket Cost for Women Who Received MRI for Breast Cancer Screening.
    • Pan IW, Oeffinger KC, Shih YT.
    • J Natl Cancer Inst. 2021 Jul 28:djab150. doi: 10.1093/jnci/djab150. Epub ahead of print.

    Press: Out-of-Pocket Costs for MRI Breast Cancer Screening Hitting More Women. (Medscape)

    • Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women.
    • Evans DG, Howell SJ, Gandhi A, van Veen EM, Woodward ER, Harvey J, Barr L, Wallace A, Lalloo F, Wilson M, Hurley E, Lim Y, Maxwell AJ, Harkness EF, Howell A.
    • Breast Cancer Res Treat. 2021 Jul 26. doi: 10.1007/s10549-021-06333-1. Epub ahead of print.
    • Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
    • Boddicker NJ, Hu C, Weitzel JN, Kraft P, Nathanson KL, Goldgar DE, Na J, Huang H, Gnanaolivu RD, Larson N, Yussuf A, Yao S, Vachon CM, Trentham-Dietz A, Teras L, Taylor JA, Scott CE, Sandler DP, Pesaran T, Patel AV, Palmer JR, Ong IM, Olson JE, O'Brien K, Neuhausen S, Martinez E, Ma H, Lindstrom S, Le Marchand L, Kooperberg C, Karam R, Hunter DJ, Hodge JM, Haiman C, Gaudet MM, Gao C, LaDuca H, Lacey JV, Dolinsky JS, Chao E, Carter BD, Burnside ES, Bertrand KA, Bernstein L, Auer PW, Ambrosone C, Yadav S, Hart SN, Polley EC, Domchek SM, Couch FJ.
    • J Clin Oncol. 2021 Jul 22:JCO2100531. doi: 10.1200/JCO.21.00531. Epub ahead of print.

    Related:

    Commentary, Research report:

    Germline Genetic Testing for Women With Breast Cancer: Shifting the Paradigm From Whom to Test to Whom NOT to Test.

    Press: Older Women with Breast Cancer May Benefit from Genetic Testing (Clinical OMICs)

    • No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families.
    • Imbert-Bouteille M, Corsini C, Picot MC, Mizrahy L, Akouete S, Huguet H, Thomas F, Geneviève D, Taourel P, Ychou M, Galibert V, Rideau C, Baudry K, Kogut Kubiak T, Coupier I, Hobeika R, Macary Y, Toledano A, Solassol J, Maalouf A, Daures JP, Pujol P.
    • Genes (Basel). 2021 Jul 20;12(7):1100. doi: 10.3390/genes12071100.
    • The Distinct Performances of Ultrasound, Mammograms, and MRI in Detecting Breast Cancer in Patients With Germline Pathogenic Variants in Cancer Predisposition Genes.
    • Liu J, Wang X, Dong L, Huang X, Zhao H, Li J, Huang S, Yuan P, Wang W, Wang J, Xing Z, Jia Z, Ming Y, Li X, Qin L, Liu G, Wu J, Li Y, Zhang M, Feng K, Ying J, Wang X.
    • Front Oncol. 2021 Jul 13;11:710156. doi: 10.3389/fonc.2021.710156.
    • Influence of aging and gadolinium exposure on T1, T2, and T2*-relaxation in healthy women with an increased risk of breast cancer with and without prior exposure to gadoterate meglumine at 3.0-T brain MR imaging.
    • Krug KB, Burke CJ, Weiss K, Baltzer PAT, Rhiem K, Maintz D, Schlamann M, Hellmich M.
    • Eur Radiol. 2021 Jul 3. doi: 10.1007/s00330-021-08069-4. Epub ahead of print.
    • Psychological consequences of MRI-based screening among women with strong family histories of breast cancer.
    • Castelo M, Brown Z, D'Abbondanza JA, Wasilewski NV, Eisen A, Muradali D, Hansen BE, Grunfeld E, Scheer AS.
    • Breast Cancer Res Treat. 2021 Jul 2. doi: 10.1007/s10549-021-06300-w. Epub ahead of print.
    • PTEN Hamartoma Tumor Syndrome/Cowden Syndrome: Genomics, Oncogenesis, and Imaging Review for Associated Lesions and Malignancy.
    • Dragoo DD, Taher A, Wong VK, Elsaiey A, Consul N, Mahmoud HS, Mujtaba B, Stanietzky N, Elsayes KM.
    • Cancers (Basel). 2021 Jun 22;13(13):3120. doi: 10.3390/cancers13133120.
    • Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.
    • Safra T, Waissengrin B, Gerber D, Bernstein-Molho R, Klorin G, Salman L, Josephy D, Chen-Shtoyerman R, Bruchim I, Frey MK, Pothuri B, Muggia F.
    • Gynecol Oncol. 2021 Jun 22:S0090-8258(21)00489-3. doi: 10.1016/j.ygyno.2021.06.009. Epub ahead of print.
    • Pancreas in Hereditary Syndromes: Cross-sectional Imaging Spectrum.
    • Katabathina VS, Buddha S, Rajebi H, Shah JN, Morani AC, Lubner MG, Dasyam A, Nazarullah A, Menias CO, Prasad SR.
    • Radiographics. 2021 Jun 18:200164. doi: 10.1148/rg.2021200164. Epub ahead of print.
    • Risk-adapted starting age of breast cancer screening in women with a family history of ovarian or other cancers: A nationwide cohort study.
    • Mukama T, Kharazmi E, Sundquist K, Sundquist J, Fallah M.
    • Cancer. 2021 Jun 15;127(12):2091-2098. doi: 10.1002/cncr.33456. Epub 2021 Feb 23.
    • Clinical practice guideline of BRCA1/2 testing for patients with breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guideline 2021.
    • Xie F, Wang S.
    • Chin Med J (Engl). 2021 Jun 4;134(13):1516-1518. doi: 10.1097/CM9.0000000000001587.
    • A systematic review of recommendations on screening strategies for breast cancer due to hereditary predisposition: Who, When, and How?
    • Cai Y, Li J, Gao Y, Yang K, He J, Li N, Tian J.
    • Cancer Med. 2021 May;10(10):3437-3448. doi: 10.1002/cam4.3898. Epub 2021 May 1.
    • Management of patients with BRCA mutation from the point of view of a breast surgeon.
    • Riis ML.
    • Ann Med Surg (Lond). 2021 Apr 16;65:102311. doi: 10.1016/j.amsu.2021.102311.
    • Cost-effectiveness of risk-based breast cancer screening: A systematic review.
    • Khan SA, Hernandez-Villafuerte KV, Muchadeyi MT, Schlander M.
    • Int J Cancer. 2021 Apr 12. doi: 10.1002/ijc.33593. Epub ahead of print.
    • Review
    • Impact of national guidelines on use of BRCA1/2 germline testing, risk management advice given to women with pathogenic BRCA1/2 variants and uptake of advice.
    • Meiser B, Kaur R, Morrow A, Peate M, Wong WKT, McPike E, Cops E, Nichols C, Austin R, Fine M, Thrupp L, Ward R, Macrae F, Hiller JE, Trainer AH, Mitchell G; ICCon Audit Study Collaborative Group.
    • Hered Cancer Clin Pract. 2021 Apr 9;19(1):24. doi: 10.1186/s13053-021-00180-3.
    • Clinico-radio-pathological Features and Biological Behavior of Breast Cancer in Young Indian Women: A Prospective Study.
    • Sudhir R, Sannapareddy K, Potlapalli A, Penmetsa V.
    • Indian J Radiol Imaging. 2021 Apr;31(2):323-332. doi: 10.1055/s-0041-1734342. Epub 2021 Jul 30.
    • Diffusion-Weighted Magnetic Resonance Imaging for Breast Cancer Screening in High-Risk Women: Design and Imaging Protocol of a Prospective Multicenter Study in Korea.
    • Shin HJ, Lee SH, Park VY, Yoon JH, Kang BJ, Yun B, Kim TH, Ko ES, Han BK, Chu AJ, Park SY, Kim HH, Moon WK.
    • J Breast Cancer. 2021 Apr;24(2):218-228. doi: 10.4048/jbc.2021.24.e19.
    • Lifestyle, behavioral, and dietary risk factors in relation to mammographic breast density in women at high risk for breast cancer.
    • Ahern TP, Sprague BL, Farina NH, Tsai E, Cuke M, Kontos D, Wood ME.
    • Cancer Epidemiol Biomarkers Prev. 2021 Feb 22:cebp.1567.2020. doi: 10.1158/1055-9965.EPI-20-1567. Epub ahead of print.
    • Post-mastectomy surveillance of BRCA1/BRCA2 mutation carriers: Outcomes from a specialized clinic for high-risk breast cancer patients.
    • Kanana N, Ben David MA, Nissan N, Yagil Y, Shalmon A, Halshtok O, Gotlieb M, Faermann R, Klang E, Samoocha D, Yassin M, Davidson T, Zippel D, Madorsky Feldman D, Friedman E, Kaidar-Person O, Sklair Levy M.
    • Breast J. 2021 Feb 11. doi: 10.1111/tbj.14190. Epub ahead of print.
    • Abnormal screens among nonmutation carriers in the High Risk Ontario Breast Screening Program.
    • Castelo M, Brown Z, Schellenberg AE, Mills JK, Eisen A, Muradali D, Grunfeld E, Scheer AS.
    • Breast J. 2021 Feb 7. doi: 10.1111/tbj.14185. Epub ahead of print.
    • Development and Implementation of an Algorithm to Guide MRI Screening in Patients With a Personal History of Treated Breast Cancer.
    • Strigel RM, Bravo E, Tevaarwerk AJ, Anderson BM, Stella AL, Neuman HB.
    • Clin Breast Cancer. 2021 Feb;21(1):26-30. doi: 10.1016/j.clbc.2020.01.005. Epub 2020 Oct 17.
    • Male Breast Cancer Risk Assessment and Screening Recommendations in High-Risk Men Who Undergo Genetic Counseling and Multigene Panel Testing.
    • Gaddam S, Heller SL, Babb JS, Gao Y.
    • Clin Breast Cancer. 2021 Feb;21(1):e74-e79. doi: 10.1016/j.clbc.2020.07.014. Epub 2020 Jul 25.
    • Implementation of a High-Risk Breast Clinic for Comprehensive Care of Women With Elevated Breast Cancer Risk Identified by Risk Assessment Models in the Community.
    • Laws A, Mulvey TM.
    • JCO Oncol Pract. 2021 Feb;17(2):e217-e225. doi: 10.1200/OP.20.00256. Epub 2020 Aug 21.
    • Experiences, expectations and preferences regarding MRI and mammography as breast cancer screening tools in women at familial risk.
    • Geuzinge HA, Heijnsdijk EAM, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MMA; FaMRIsc study group.
    • Breast. 2021 Jan 18;56:1-6. doi: 10.1016/j.breast.2021.01.002. Epub ahead of print.
    • Intensivierte Früherkennung mittels Magnetresonanztomographie in der Hochrisikosituation [High-risk screening using magnetic resonance imaging].
    • Bick U.
    • Radiologe. 2021 Jan 12. German. doi: 10.1007/s00117-020-00797-w. Epub ahead of print.
    • Review, [Article in German]
    • Screening and Preventative Strategies for Patients at High Risk for Breast Cancer.
    • Ter-Minassian M, Schaeffer ML, Jefferson CR, Shapiro SC, Suwannarat P, Visvanathan K.
    • JCO Oncol Pract. 2021 Jan 11:OP2000262. doi: 10.1200/OP.20.00262. Epub ahead of print.
    • Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    • Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML; CGC, Karlan BY, Khan S, Klein C, Kohlmann W; CGC, Kurian AW, Laronga C, Litton JK, Mak JS; LCGC, Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G; CGC, Senter-Jamieson L; CGC, Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA.
    • J Natl Compr Canc Netw. 2021 Jan 6;19(1):77-102. doi: 10.6004/jnccn.2021.0001.
    • The clinicopathological and MRI features of patients with BRCA1/2 mutations in familial breast cancer.
    • You C, Xiao Q, Zhu X, Sun Y, Di G, Liu G, Hou Y, Chen C, Wu J, Shao Z, Gu Y, Hu Z.
    • Gland Surg. 2021 Jan;10(1):262-272. doi: 10.21037/gs-20-596.
    • The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study.
    • Seiffert K, Thoene K, Eulenburg CZ, Behrens S, Schmalfeldt B, Becher H, Chang-Claude J, Witzel I.
    • Breast. 2020 Dec 24;55:98-104. doi: 10.1016/j.breast.2020.12.008. Epub ahead of print.
    • Trends in screening breast magnetic resonance imaging use among US women, 2006 to 2016.
    • Wernli KJ, Callaway KA, Henderson LM, Kerlikowske K, Lee JM, Ross-Degnan D, Wallace JK, Wharam JF, Zhang F, Stout NK.
    • Cancer. 2020 Dec 15;126(24):5293-5302. doi: 10.1002/cncr.33140. Epub 2020 Sep 28.
    • Long-Term Evaluation of Women Referred to a Breast Cancer Family History Clinic (Manchester UK 1987-2020).
    • Howell A, Gandhi A, Howell S, Wilson M, Maxwell A, Astley S, Harvie M, Pegington M, Barr L, Baildam A, Harkness E, Hopwood P, Wisely J, Wilding A, Greenhalgh R, Affen J, Maurice A, Cole S, Wiseman J, Lalloo F, French DP, Evans DG.
    • Cancers (Basel). 2020 Dec 9;12(12):3697. doi: 10.3390/cancers12123697.
    • Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study.
    • Watt GP, Sung J, Morris EA, Buys SS, Bradbury AR, Brooks JD, Conant EF, Weinstein SP, Kontos D, Woods M, Colonna SV, Liang X, Stein MA, Pike MC, Bernstein JL.
    • Breast Cancer Res. 2020 Dec 7;22(1):138. doi: 10.1186/s13058-020-01375-7. PMID: 33287857.
    • Beyond the AJR: "Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk".
    • Lowry KP, Sippo DA.
    • AJR Am J Roentgenol. 2020 Nov 25. doi: 10.2214/AJR.20.25138. Epub ahead of print.
    • Commentary

    Related:

    Original research:

    Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.

    • Breast Cancer Mortality among Women with a BRCA1 or BRCA2 Mutation in a Magnetic Resonance Imaging Plus Mammography Screening Program.
    • Warner E, Zhu S, Plewes DB, Hill K, Ramsay EA, Causer PA, Seely J, Jong RA, Lenkov P, Elser C, Crystal P, Yaffe MJ, Giannakeas V, Sun P, Narod SA.
    • Cancers (Basel). 2020 Nov 23;12(11):3479. doi: 10.3390/cancers12113479.
    • Radiologic-Histopathologic Correlation of Transvaginal US and Risk-reducing Salpingo-oophorectomy for Women at High Risk for Tubo-ovarian Carcinoma.
    • Sakala MD, Curci NE, Masch WR, Mendiratta-Lala M, Stein EB, Wasnik AP, Sciallis AP, Uppal S, Pearlman MD, Maturen KE.
    • Radiol Imaging Cancer. 2020 Nov 13;2(6):e190086. doi: 10.1148/rycan.2020190086.
    • Comparison of interval breast cancers with 2D digital mammography versus 3D digital breast tomosynthesis in a large community-based practice.
    • Winter AM, Kazmi S, Hardy AK, Bennett DL.
    • Breast J. 2020 Oct 16. doi: 10.1111/tbj.14047. Epub ahead of print.
    • Germline BRCA 1-2 status prediction through ovarian ultrasound images radiogenomics: a hypothesis generating study (PROBE study).
    • Nero C, Ciccarone F, Boldrini L, Lenkowicz J, Paris I, Capoluongo ED, Testa AC, Fagotti A, Valentini V, Scambia G.
    • Sci Rep. 2020 Oct 5;10(1):16511. doi: 10.1038/s41598-020-73505-2.
    • Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers.
    • Fong A, Cass I, John C, Gillen J, Moore KM, Gangi A, Walsh C, Li AJ, Rimel BJ, Karlan BY, Amersi F.
    • Am Surg. 2020 Oct;86(10):1243-1247. doi: 10.1177/0003134820964208. Epub 2020 Oct 26.
    • Advances in epithelial ovarian cancer.
    • Neesham D, Richards A, McGauran M.
    • Aust J Gen Pract. 2020 Oct;49(10):665-669.
    • Breast cancer screening in women at high risk of hereditary breast cancer: an Australian experience.
    • Bennett I, Tourani S, Cockburn L, Reasbeck J, Grobbelaar N, Dann S, Patrikios P, Brazier J.
    • ANZ J Surg. 2020 Sep 30. doi: 10.1111/ans.16320. Epub ahead of print.
    • Genetic Testing and Surveillance of Young Breast Cancer Survivors and Blood Relatives: A Cluster Randomized Trial.
    • Katapodi MC, Ming C, Northouse LL, Duffy SA, Duquette D, Mendelsohn-Victor KE, Milliron KJ, Merajver SD, Dinov ID, Janz NK.
    • Cancers (Basel). 2020 Sep 5;12(9):2526. doi: 10.3390/cancers12092526.
    • Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
    • Geuzinge HA, Obdeijn IM, Rutgers EJT, Saadatmand S, Mann RM, Oosterwijk JC, Tollenaar RAEM, de Roy van Zuidewijn DBW, Lobbes MBI, van 't Riet M, Hooning MJ, Ausems MGEM, Loo CE, Wesseling J, Luiten EJT, Zonderland HM, Verhoef C, Heijnsdijk EAM, Tilanus-Linthorst MMA, de Koning HJ; Familial MRI Screening (FaMRIsc) Study group.
    • JAMA Oncol. 2020 Sep 1;6(9):1381-1389. doi: 10.1001/jamaoncol.2020.2922.

    Related:

    Commentary:

    Beyond the AJR: "Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk".

    • Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History.
    • van den Broek JJ, Schechter CB, van Ravesteyn NT, Janssens ACJW, Wolfson MC, Trentham-Dietz A, Simard J, Easton DF, Mandelblatt JS, Kraft P, de Koning HJ.
    • J Natl Cancer Inst. 2020 Aug 27. pii: djaa127. doi: 10.1093/jnci/djaa127. [Epub ahead of print]
    • Screening women at high risk for breast cancer: one program fits all? : Subgroup analysis of a large population high risk breast screening program.
    • Hermann N, Klil-Drori A, Angarita FA, Westergard S, Freitas V, Scaranelo A, McCready DR, Cil TD.
    • Breast Cancer Res Treat. 2020 Aug 26. doi: 10.1007/s10549-020-05895-w. Epub ahead of print.
    • Breast imaging, breast surgery, and cancer genetics in the age of COVID-19.
    • Yin K, Singh P, Drohan B, Hughes KS.
    • Cancer. 2020 Aug 4. doi: 10.1002/cncr.33113. Epub ahead of print.
    • Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer.
    • Wood ME, McKinnon W, Garber J.
    • Breast J. 2020 Aug 2. doi: 10.1111/tbj.13969. Epub ahead of print.
    • Review
    • Evidence for Increased Susceptibility for Breast Cancer from Exposure to Ionizing Radiation Due to Familial Breast Cancer History: Results from the Swedish Hemangioma Cohort.
    • Eidemüller M, Holmberg E, Lundell M, Karlsson P.
    • Am J Epidemiol. 2020 Jul 31:kwaa163. doi: 10.1093/aje/kwaa163. Epub ahead of print.
    • Breast MRI texture analysis for prediction of BRCA-associated genetic risk.
    • Vasileiou G, Costa MJ, Long C, Wetzler IR, Hoyer J, Kraus C, Popp B, Emons J, Wunderle M, Wenkel E, Uder M, Beckmann MW, Jud SM, Fasching PA, Cavallaro A, Reis A, Hammon M.
    • BMC Med Imaging. 2020 Jul 29;20(1):86. doi: 10.1186/s12880-020-00483-2.
    • Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer.
    • Collins JM, Isaacs C.
    • Breast J. 2020 Jul 11. doi: 10.1111/tbj.13970. Epub ahead of print.
    • Review
    • Current status of MRI-guided vacuum-assisted breast biopsy in Japan.
    • Takahama N, Tozaki M, Ohgiya Y.
    • Breast Cancer. 2020 Jul 6. doi: 10.1007/s12282-020-01107-x. Epub ahead of print.
    • Review, Commentary
    • Current status of breast cancer screening in high-risk women in Japan.
    • Tozaki M, Nakamura S.
    • Breast Cancer. 2020 Jul 6. doi: 10.1007/s12282-020-01103-1. Epub ahead of print.
    • Review
    • Dynamic contrast-enhanced magnetic resonance imaging for risk-stratified screening in women with BRCA mutations or high familial risk for breast cancer: are we there yet?
    • Whitaker KD, Sheth D, Olopade OI.
    • Breast Cancer Res Treat. 2020 Jul 3. doi: 10.1007/s10549-020-05759-3. Epub ahead of print.
    • Review
    • Improved characterization of sub-centimeter enhancing breast masses on MRI with radiomics and machine learning in BRCA mutation carriers.
    • Lo Gullo R, Daimiel I, Rossi Saccarelli C, Bitencourt A, Gibbs P, Fox MJ, Thakur SB, Martinez DF, Jochelson MS, Morris EA, Pinker K.
    • Eur Radiol. 2020 Jun 27. doi: 10.1007/s00330-020-06991-7. Epub ahead of print.
    • Risk stratification in breast cancer screening: cost-effectiveness and harm-benefit ratios for low-risk and high-risk women.
    • Sankatsing VDV, van Ravesteyn NT, Heijnsdijk EAM, Broeders MJM, de Koning HJ.
    • Int J Cancer. 2020 Jun 2. doi: 10.1002/ijc.33126. Epub ahead of print.
    • Risk Management for BRCA1/BRCA2 mutation carriers without and with breast cancer.
    • Mainor CB, Isaacs C.
    • Curr Breast Cancer Rep. 2020 Jun;12(2):66-74. doi: 10.1007/s12609-019-00350-2. Epub 2020 Feb 17.
    • Review
    • Managing a woman with BRCA mutations? Shared decision-making is key.
    • Schrager S, Torell E, Ledford K, Elezaby M, Barroleit L, Sadowski E.
    • J Fam Pract. 2020 Jun;69(5):237-243.
    • Genetic Testing and Screening Recommendations for Patients with Hereditary Breast Cancer.
    • Bharucha PP, Chiu KE, François FM, Scott JL, Khorjekar GR, Tirada NP.
    • Radiographics. 2020 May 29:190181. doi: 10.1148/rg.2020190181. Epub ahead of print.
    • Review

    Related:

    Commentary:

    Invited Commentary: Breast Cancer Risk Assessment and Screening Strategies-What's New?

    • Evaluation of breast screening strategies in a high risk breast and ovarian cancer clinic.
    • Knisely AT, Stewart ME, Garcia C, Thomas MH, Modesitt SC, Ring KL.
    • Gynecol Oncol Rep. 2020 May 22;33:100587. doi: 10.1016/j.gore.2020.100587.
    • Breast cancer survival following MRI detection in a high-risk screening program.
    • Hollingsworth AB, Pearce MR, Stough RG.
    • Breast J. 2020 May;26(5):991-994. doi: 10.1111/tbj.13813. Epub 2020 Mar 12.
    • The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers.
    • Obdeijn IM, Mann RM, Loo CCE, Lobbes M, Voormolen EMC, van Deurzen CHM, de Bock G; Hereditary Breast Ovarian Cancer Research Group Netherlands (HEBON), Hooning MJ.
    • Breast Cancer Res Treat. 2020 Apr 24. doi: 10.1007/s10549-020-05642-1. [Epub ahead of print]
    • Surveillance for second breast cancer events in women with a personal history of breast cancer using breast MRI: a systematic review and meta-analysis.
    • Haas CB, Nekhlyudov L, Lee JM, Javid SH, Bush M, Johnson D, Gleason T, Kaufman C, Specht J, Stitham S, Wernli KJ.
    • Breast Cancer Res Treat. 2020 Apr 17. doi: 10.1007/s10549-020-05637-y. [Epub ahead of print]
    • Review
    • Comparison of mammography behaviors, health beliefs, and fear levels of women with and without familial breast cancer history.
    • Erdogan E, Tuzcu A.
    • Women Health. 2020 Apr 6:1-16. doi: 10.1080/03630242.2020.1746949. [Epub ahead of print]
    • Does Medicare-eligible high-risk breast cancer screening MRI target the right women?
    • Lo G, McLaughlin A, Jacques A, Dhillon R, Porter G, Jayaratne T, Bose S, Bourke A.
    • J Med Imaging Radiat Oncol. 2020 Apr;64(2):220-228. doi: 10.1111/1754-9485.13009. Epub 2020 Feb 9.
    • Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations.
    • Haque R, Skates SJ, Armstrong MA, Lentz SE, Anderson M, Jiang W, Alvarado MM, Chillemi G, Shaw SF, Kushi LH, Powell CB.
    • Gynecol Oncol. 2020 Mar 4. pii: S0090-8258(20)30164-5. doi: 10.1016/j.ygyno.2020.02.027. [Epub ahead of print]
    • BRCA and Beyond: Comprehensive Image-rich Review of Hereditary Breast and Gynecologic Cancer Syndromes.
    • Chung SH, Woldenberg N, Roth AR, Masamed R, Conlon W, Cohen JG, Joines MM, Patel MK.
    • Radiographics. 2020 Mar-Apr;40(2):306-325. doi: 10.1148/rg.2020190084. Epub 2020 Feb 7.
    • Review
    • Healthcare Utilization and Costs after Receiving a Positive BRCA1/2 Result from a Genomic Screening Program.
    • Hao J, Hassen D, Manickam K, Murray MF, Hartzel DN, Hu Y, Liu K, Rahm AK, Williams MS, Lazzeri A, Buchanan A, Sturm A, Snyder SR.
    • J Pers Med. 2020 Feb 3;10(1). pii: E7. doi: 10.3390/jpm10010007.
    • Cost-effectiveness of long-term clinical management of BRCA pathogenic variant carriers.
    • Petelin L, Hossack L, Shanahan M, Mitchell G, Liew D, James PA, Trainer AH.
    • Genet Med. 2020 Jan 30. doi: 10.1038/s41436-020-0751-3. [Epub ahead of print]
    • Radiographic Surveillance of Patients with Non-BRCA1/2 Pathogenic Variants.
    • Hudson L, Gower N, Lenarcic S, Trufan SJ, White RL Jr.
    • Ann Surg Oncol. 2020 Jan 23. doi: 10.1245/s10434-019-08191-0. [Epub ahead of print]
    • Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers.
    • Weidner AE, Liggin ME, Zuniga BI, Tezak AL, Wiesner GL, Pal T.
    • Cancer. 2020 Jan 22. doi: 10.1002/cncr.32715. [Epub ahead of print]
    • Imaging Features of Triple Negative Breast Cancer and the Effect of BRCA Mutations.
    • Karbasian N, Sohrabi S, Omofoye TS, Le-Petross H, Arun BK, Albarracin CT, Hess KR, Gutierrez-Barrera AM, Whitman GJ.
    • Curr Probl Diagn Radiol. 2020 Jan 8. pii: S0363-0188(20)30016-5. doi: 10.1067/j.cpradiol.2020.01.011. [Epub ahead of print]
    • The relationship of breast density in mammography and magnetic resonance imaging in women with triple negative breast cancer.
    • Mema E, Schnabel F, Chun J, Kaplowitz E, Price A, Goodgal J, Moy L.
    • Eur J Radiol. 2020 Jan 7;124:108813. doi: 10.1016/j.ejrad.2020.108813. [Epub ahead of print]
    • What Surveillance Would You Recommend to a Patient with a BRCA Mutation Who Declines Prophylactic Surgery?
    • Domchek S.
    • Medscape. Oncology Decision Point. 2019 Dec 27.
    • Gadolinium Retention and Breast MRI Screening: More Harm Than Good?
    • Sardanelli F, Cozzi A, Trimboli RM, Schiaffino S.
    • AJR Am J Roentgenol. 2019 Dec 4:1-4. doi: 10.2214/AJR.19.21988. [Epub ahead of print]
    • Image-based screening for men at high risk for breast cancer: Benefits and drawbacks.
    • Woods RW, Salkowski LR, Elezaby M, Burnside ES, Strigel RM, Fowler AM.
    • Clin Imaging. 2019 Nov 28;60(1):84-89. doi: 10.1016/j.clinimag.2019.11.005. [Epub ahead of print]
    • Review
    • Sporadic implementation of UK familial mammographic surveillance guidelines 15 years after original publication.
    • Evans DG, Edwards M, Duffy SW; Cancer Genetics Group clinical leads, Tischkowitz M.
    • Br J Cancer. 2019 Nov 25. doi: 10.1038/s41416-019-0631-2. [Epub ahead of print]
    • Risk-based breast cancer screening strategies in women.
    • Harkness EF, Astley SM, Evans DG.
    • Best Pract Res Clin Obstet Gynaecol. 2019 Nov 18. pii: S1521-6934(19)30169-5. doi: 10.1016/j.bpobgyn.2019.11.005. [Epub ahead of print]
    • Risk-Adapted Starting Age of Screening for Relatives of Patients With Breast Cancer.
    • Mukama T, Kharazmi E, Xing X, Sundquist K, Sundquist J, Brenner H, Fallah M.
    • JAMA Oncol. 2019 Nov 14. doi: 10.1001/jamaoncol.2019.3876. [Epub ahead of print]

    Related:

    Editorial:

    Toward Risk-Stratified Breast Cancer Screening: Considerations for Changes in Screening Guidelines.

    Editorial:

    Breast cancer screening programs: does one risk fit all?

    Letter, Comment:

    Determining the Appropriate Risk-Adapted Screening Age for Familial Breast Cancer.

    Letter, Reply:

    Determining the Appropriate Risk-Adapted Screening Age for Familial Breast Cancer-Reply.

    • Prophylactic breast irradiation reduces background parenchymal enhancement (BPE) on MRI: A secondary analysis.
    • Ben-David MA, Corn BW, Evron E, Goldberg H, Pfeffer RM, Abdah-Bortnyak R, Matceyevsky D, Weinstein Y, Golan O, Sklair-Levy M.
    • Breast. 2019 Nov 6;49:70-73. doi: 10.1016/j.breast.2019.10.011. [Epub ahead of print]
    • Breast cancer surveillance for BRCA1/2 mutation carriers - is "early detection" early enough?
    • Bernstein-Molho R, Kaufman B, Ben David MA, Sklair-Levy M, Feldman DM, Zippel D, Laitman Y, Friedman E.
    • Breast. 2019 Nov 6;49:81-86. doi: 10.1016/j.breast.2019.10.012. [Epub ahead of print]
    • Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    • Vysotskaia V, Kaseniit KE, Bucheit L, Ready K, Price K, Johansen Taber K.
    • Cancer. 2019 Nov 4. doi: 10.1002/cncr.32572. [Epub ahead of print]
    • Impact of Genetic Testing on Risk-Management Behavior of Black Breast Cancer Survivors: A Longitudinal, Observational Study.
    • Conley CC, Kasting ML, Augusto BM, Garcia JD, Cragun D, Gonzalez BD, Kim J, Ashing KT, Knott CL, Hughes-Halbert C, Pal T, Vadaparampil ST.
    • Ann Surg Oncol. 2019 Nov 1. doi: 10.1245/s10434-019-07982-9. [Epub ahead of print]
    • 2019 exceptional surveillance of familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (NICE guideline CG164) [Internet].
    • NICE Surveillance programme project team: Nolan K, Allaby M, McFarlane E, Haynes C.
    • London: National Institute for Health and Care Excellence (UK); 2019 Nov.
    • Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer.
    • [No author given]
    • National Institute for Health and Care Excellence (UK): Clinical Guidelines; 2013 Jun. [Last Update: November 2019.]
    • Outcomes of women at high familial risk for breast cancer: An 8-year single-center experience.
    • Lammert J, Skandarajah AR, Shackleton K, Calder P, Thomas S, Lindeman GJ, Mann GB.
    • Asia Pac J Clin Oncol. 2019 Oct 28. doi: 10.1111/ajco.13274. [Epub ahead of print]
    • Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study.
    • Cao CX, Sharib JS, Blanco AM, Goldberg D, Bracci P, Mukhtar RA, Esserman LJ, Kirkwood KS.
    • J Am Coll Surg. 2019 Oct 21. pii: S1072-7515(19)32137-4. doi: 10.1016/j.jamcollsurg.2019.09.019. [Epub ahead of print]
    • Breast Cancer Screening in High-Risk Men: A 12-Year Longitudinal Observational Study of Male Breast Imaging Utilization and Outcomes.
    • Gao Y, Goldberg JE, Young TK, Babb JS, Moy L, Heller SL.
    • Radiology. 2019 Sep 17:190971. doi: 10.1148/radiol.2019190971. [Epub ahead of print]

    Related:

    Press: Men at High Risk for Breast Cancer May Benefit From Screening. (Medscape Oncology)

    • Breast Cancer Screening in BRCA Mutation Carriers: Necessity of a Relevant Update of Mammographic Modalities.
    • Colin C, Doutriaux-Dumoulin I.
    • Radiology. 2019 Sep 3:191306. doi: 10.1148/radiol.2019191306. [Epub ahead of print]
    • Letter, Comment

    Related:

    Original research:

    BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations.

    • Hereditary breast cancer: screening and risk reducing surgery.
    • Renzulli M, Zanotti S, Clemente A, Mineo G, Tovoli F, Reginelli A, Barile A, Cappabianca S, Taffurelli M, Golfieri R.
    • Gland Surg. 2019 Sep;8(Suppl 3):S142-S149. doi: 10.21037/gs.2019.04.04.
    • Pilot study of rapid MR pancreas screening for patients with BRCA mutation.
    • Corrias G, Raeside MC, Agostini A, Huicochea-Castellanos S, Aramburu-Nunez D, Paudyal R, Shukla-Dave A, Smelianskaia O, Capanu M, Zheng J, Fung M, Kelsen DP, Mangino DA, Robson ME, Goldfrank DJ, Carter J, Allen PJ, Conti B, Monti S, Do RKG, Mannelli L.
    • Eur Radiol. 2019 Aug;29(8):3976-3985. doi: 10.1007/s00330-018-5975-0. Epub 2019 Jan 28.
    • Contrast-enhanced MRI for breast cancer screening.
    • Mann RM, Kuhl CK, Moy L.
    • J Magn Reson Imaging. 2019 Aug;50(2):377-390. doi: 10.1002/jmri.26654. Epub 2019 Jan 18.
    • MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.
    • Saadatmand S, Geuzinge HA, Rutgers EJT, Mann RM, de Roy van Zuidewijn DBW, Zonderland HM, Tollenaar RAEM, Lobbes MBI, Ausems MGEM, van 't Riet M, Hooning MJ, Mares-Engelberts I, Luiten EJT, Heijnsdijk EAM, Verhoef C, Karssemeijer N, Oosterwijk JC, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MMA; FaMRIsc study group.
    • Lancet Oncol. 2019 Aug;20(8):1136-1147. doi: 10.1016/S1470-2045(19)30275-X. Epub 2019 Jun 17.

    Related:

    Comment:

    Underdiagnosis is the main challenge in breast cancer screening.

    Letter, Commentary:

    MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc).

    Research news: MRI or mammograms for detecting breast cancer in families with unknown genetic mutations? (FORCE. XRAYS.)

    • Conspicuity of Screen-Detected Malignancies on Full Field Digital Mammography vs. Synthetic Mammography.
    • Chikarmane SA, Yeh ED, Wang A, Ratanaprasatporn L, Giess CS.
    • Acad Radiol. 2019 Jul 12. pii: S1076-6332(19)30312-5. doi: 10.1016/j.acra.2019.06.008. [Epub ahead of print]
    • Mammographic screening in male patients at high risk for breast cancer: is it worth it?
    • Marino MA, Gucalp A, Leithner D, Keating D, Avendano D, Bernard-Davila B, Morris EA, Pinker K, Jochelson MS.
    • Breast Cancer Res Treat. 2019 Jul 6. doi: 10.1007/s10549-019-05338-1. [Epub ahead of print]
    • Willingness to decrease mammogram frequency among women at low risk for hereditary breast cancer.
    • Guan Y, Nehl E, Pencea I, Condit CM, Escoffery C, Bellcross CA, McBride CM.
    • Sci Rep. 2019 Jul 3;9(1):9599. doi: 10.1038/s41598-019-45967-6.
    • Predictors of mammographic density among women with a strong family history of breast cancer.
    • Moran O, Eisen A, Demsky R, Blackmore K, Knight JA, Panchal S, Ginsburg O, Zbuk K, Yaffe M, Metcalfe KA, Narod SA, Kotsopoulos J.
    • BMC Cancer. 2019 Jun 26;19(1):631. doi: 10.1186/s12885-019-5855-2.
    • Performance measures of magnetic resonance imaging plus mammography in the High Risk Ontario Breast Screening Program.
    • Chiarelli AM, Blackmore KM, Muradali D, Done SJ, Majpruz V, Weerasinghe A, Mirea L, Eisen A, Rabeneck L, Warner E.
    • J Natl Cancer Inst. 2019 Jun 24. pii: djz079. doi: 10.1093/jnci/djz079. [Epub ahead of print]

    Related:

    Editorial:

    Breast cancer screening in high-risk women: is MRI alone enough?

    • Annual versus biennial screening: diagnostic accuracy among concurrent cohorts within the Ontario Breast Screening Program.
    • Chiarelli AM, Blackmore KM, Mirea L, Done SJ, Majpruz V, Weerasinghe A, Rabeneck L, Muradali D.
    • J Natl Cancer Inst. 2019 Jun 24. pii: djz131. doi: 10.1093/jnci/djz131. [Epub ahead of print]
    • Artificial Intelligence-Based Classification of Breast Lesions Imaged With a Multiparametric Breast MRI Protocol With Ultrafast DCE-MRI, T2, and DWI.
    • Dalmiş MU, Gubern-Mérida A, Vreemann S, Bult P, Karssemeijer N, Mann R, Teuwen J.
    • Invest Radiol. 2019 Jun;54(6):325-332. doi: 10.1097/RLI.0000000000000544.
    • Performance of Screening Breast MRI across Women with Different Elevated Breast Cancer Risk Indications.
    • Sippo DA, Burk KS, Mercaldo SF, Rutledge GM, Edmonds C, Guan Z, Hughes KS, Lehman CD.
    • Radiology. 2019 May 7:181136. doi: 10.1148/radiol.2019181136. [Epub ahead of print]
    • Differences between screen-detected and interval breast cancers among BRCA mutation carriers.
    • Pilewskie M, Zabor EC, Gilbert E, Stempel M, Petruolo O, Mangino D, Robson M, Jochelson MS.
    • Breast Cancer Res Treat. 2019 May;175(1):141-148. doi: 10.1007/s10549-018-05123-6. Epub 2019 Jan 23.
    • BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations.
    • Elezaby M, Lees B, Maturen KE, Barroilhet L, Wisinski KB, Schrager S, Wilke LG, Sadowski E.
    • Radiology. 2019 Apr 30:181814. doi: 10.1148/radiol.2019181814. [Epub ahead of print]

    Related:

    Letter, Comment:

    Breast Cancer Screening in BRCA Mutation Carriers: Necessity of a Relevant Update of Mammographic Modalities.

    • "A natural progression" - Australian women's attitudes about an individualised breast screening model.
    • Lippey J, Keogh LA, Mann GB, Campbell IG, Forrest LE.
    • Cancer Prev Res (Phila). 2019 Apr 19. pii: canprevres.0443.2018. doi: 10.1158/1940-6207.CAPR-18-0443. [Epub ahead of print]
    • Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
    • Shimada S, Yoshida R, Nakashima E, Kitagawa D, Gomi N, Horii R, Takeuchi S, Ashihara Y, Kita M, Akiyama F, Ohno S, Saito M, Arai M.
    • Breast Cancer. 2019 Apr 12. doi: 10.1007/s12282-019-00971-6. [Epub ahead of print]
    • International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.
    • Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, Pal T, Lynch HT, Tung NM, Kwong A, Ainsworth P, Karlan B, Moller P, Eng C, Weitzel JN, Sun P, Lubinski J, Narod SA; Hereditary Breast Cancer Clinical Study Group.
    • Br J Cancer. 2019 Apr 11. doi: 10.1038/s41416-019-0446-1. [Epub ahead of print]

    Related:

    Editorial:

    Cancer screening and prevention in BRCA mutation carriers: a missed opportunity?

    • Clinical findings and outcomes of MRI staging of breast cancer in a diverse population.
    • Raghavendra A, Wecsler J, Ji L, Sheth P, Ricker C, Church T, Sposto R, Lang J, Sener S, Larsen L, Tripathy D.
    • Breast Cancer Res Treat. 2019 Apr;174(2):315-324. doi: 10.1007/s10549-018-05084-w. Epub 2018 Dec 12.
    • Review
    • Yield of surveillance magnetic resonance imaging after bilateral mastectomy and reconstruction: a retrospective cohort study.
    • Golan O, Amitai Y, Barnea Y, Menes TS.
    • Breast Cancer Res Treat. 2019 Apr;174(2):463-468. doi: 10.1007/s10549-018-05077-9. Epub 2018 Dec 3.
    • Effect of Background Parenchymal Enhancement on Cancer Risk Across Different High-Risk Patient Populations Undergoing Screening Breast MRI.
    • Sippo DA, Rutledge GM, Burk KS, Mercaldo SF, Dontchos BN, Edmonds CE, Lehman CD.
    • AJR Am J Roentgenol. 2019 Mar 19:1-7. doi: 10.2214/AJR.18.20566. [Epub ahead of print]
    • Prenatal genetic counselors' practices and confidence level when counseling on cancer risk identified on expanded carrier screening.
    • Thompson J, Vogel Postula K, Wong K, Spencer S.
    • J Genet Couns. 2019 Mar 19. doi: 10.1002/jgc4.1118. [Epub ahead of print]
    • Performance of Screening Ultrasonography as an Adjunct to Screening Mammography in Women Across the Spectrum of Breast Cancer Risk.
    • Lee JM, Arao RF, Sprague BL, Kerlikowske K, Lehman CD, Smith RA, Henderson LM, Rauscher GH, Miglioretti DL.
    • JAMA Intern Med. 2019 Mar 18. doi: 10.1001/jamainternmed.2018.8372. [Epub ahead of print]
    • Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers.
    • Guindalini RSC, Zheng Y, Abe H, Whitaker K, Yoshimatsu TF, Walsh T, Schacht D, Kulkarni K, Sheth D, Verp MS, Bradbury AR, Churpek J, Obeid E, Mueller J, Khramtsova G, Liu F, Raoul A, Cao H, Romero IL, Hong S, Livingston R, Jaskowiak N, Wang X, Debiasi M, Pritchard CC, King MC, Karczmar G, Newstead GM, Huo D, Olopade OI.
    • Clin Cancer Res. 2019 Mar 15;25(6):1786-1794. doi: 10.1158/1078-0432.CCR-18-0200. Epub 2018 Aug 28.

    Related:

    Review, Research news:

    More Is More: Semiannual Breast MRI Screening in BRCA1 Mutation Carriers.

    • Should women with a BRCA1/2 mutation aged 60 and older be offered intensified breast cancer screening? - A cost-effectiveness analysis.
    • Phi XA, Greuter MJW, Obdeijn IM, Oosterwijk JC, Feenstra TL, Houssami N, de Bock GH.
    • Breast. 2019 Mar 12;45:82-88. doi: 10.1016/j.breast.2019.03.004. [Epub ahead of print]
    • Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories?
    • Cortesi L, Canossi B, Battista R, Pecchi A, Drago A, Dal Molin C, Toss A, De Matteis E, Marchi I, Torricelli P, Cascinu S.
    • Int J Cancer. 2019 Mar 1;144(5):1001-1009. doi: 10.1002/ijc.31794. Epub 2018 Oct 4.
    • High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.
    • Bick U, Engel C, Krug B, Heindel W, Fallenberg EM, Rhiem K, Maintz D, Golatta M, Speiser D, Rjosk-Dendorfer D, Lämmer-Skarke I, Dietzel F, Schäfer KWF, Leinert E, Weigel S, Sauer S, Pertschy S, Hofmockel T, Hagert-Winkler A, Kast K, Quante A, Meindl A, Kiechle M, Loeffler M, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).
    • Breast Cancer Res Treat. 2019 May;175(1):217-228. doi: 10.1007/s10549-019-05152-9. Epub 2019 Feb 6.
    • Trends in Breast MRI Use Among Women with BRCA Mutations: A National Claims Analysis 2006–2016.
    • Wernli KJ, Callaway KA, Henderson LM, Kerlikowske K, Lee JM, Ross-Degnan D, Wallace JK, Wharam JF, Zhang F, Stout NK.
    • Cancer Epidemiol Biomarkers Prev. 2019 Mar;28(3):624. doi: 10.1158/1055-9965.EPI-19-0079.
    • Conference abstract
    • Breast Cancer Screening: Why Can't Everyone Agree?
    • Jordan V, Khan M, Prill D.
    • Prim Care. 2019 Mar;46(1):97-115. doi: 10.1016/j.pop.2018.10.010. Epub 2018 Dec 22.
    • Review
    • Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses.
    • Petralia G, Padhani AR, Pricolo P, Zugni F, Martinetti M, Summers PE, Grazioli L, Colagrande S, Giovagnoni A, Bellomi M; Italian Working Group on Magnetic Resonance.
    • Radiol Med. 2019 Mar;124(3):218-233. doi: 10.1007/s11547-018-0955-7. Epub 2018 Nov 14.
    • Review
    • The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan.
    • Murakami W, Tozaki M, Nakamura S, Ide Y, Inuzuka M, Hirota Y, Murakami K, Takahama N, Ohgiya Y, Gokan T.
    • Breast Cancer. 2019 Feb 28. doi: 10.1007/s12282-019-00955-6. [Epub ahead of print]
    • Breast ultrasound in high-risk women.
    • Cortesi L, Barbieri E, Toss A.
    • Oncotarget. 2019 Feb 22;10(16):1552-1553. doi: 10.18632/oncotarget.26713. eCollection 2019 Feb 22.
    • Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom.
    • Autier P.
    • JAMA Oncol. 2019 Jan 17. doi: 10.1001/jamaoncol.2018.6501. [Epub ahead of print]
    • Letter, Comment

    Related:

    Letter, Reply:

    Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom-Reply.

    Original research:

    Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.

    • The Impact of a Risk-Based Breast Cancer Screening Decision Aid on Initiation of Mammography Among Younger Women: Report of a Randomized Trial.
    • Schapira MM, Hubbard RA, Seitz HH, Conant EF, Schnall M, Cappella JN, Harrington T, Inge C, Armstrong K.
    • MDM Policy Pract. 2019 Jan 17;4(1):2381468318812889. doi: 10.1177/2381468318812889. eCollection 2019 Jan-Jun.
    • Relationship between Background Parenchymal Enhancement on High-risk Screening MRI and Future Breast Cancer Risk.
    • Grimm LJ, Saha A, Ghate SV, Kim C, Soo MS, Yoon SC, Mazurowski MA.
    • Acad Radiol. 2019 Jan;26(1):69-75. doi: 10.1016/j.acra.2018.03.013. Epub 2018 Mar 27.
    • Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35-39 at Increased Familial Risk of Breast Cancer.
    • Evans DG, Thomas S, Caunt J, Burch A, Brentnall AR, Roberts L, Howell A, Wilson M, Fox R, Hillier S, Sibbering DM, Moss S, Wallis MG, Eccles DM; FH02 study group, Duffy S.
    • EClinicalMedicine. 2019 Jan;7:39-46. doi: 10.1016/j.eclinm.2019.01.005.
    • False-positive screening events and worry influence decisions about surgery among high-risk women.
    • Andersen MR, Karlan BY, Drescher CW, Paley P, Hawley S, Palomares M, Daly MB, Urban N.
    • Health Psychol. 2019 Jan;38(1):43-52. doi: 10.1037/hea0000647. Epub 2018 Nov 15.
    • High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan.
    • Yamauchi H, Okawa M, Yokoyama S, Nakagawa C, Yoshida R, Suzuki K, Nakamura S, Arai M.
    • Breast Cancer Res Treat. 2018 Dec;172(3):679-687. doi: 10.1007/s10549-018-4953-1. Epub 2018 Sep 10.
    • Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer.
    • Warner E.
    • Cancers (Basel). 2018 Nov 30;10(12). pii: E477. doi: 10.3390/cancers10120477.
    • Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.
    • Pashayan N, Morris S, Gilbert FJ, Pharoah PDP.
    • JAMA Oncol. 2018 Nov 1;4(11):1504-1510. doi: 10.1001/jamaoncol.2018.1901.

    Related:

    Editorial:

    Implementation Challenges for Risk-Stratified Screening in the Era of Precision Medicine.

    Audio Interview: Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Breast Cancer Screening. (JAMA Oncology)

    Press: Breast Cancer Screening Only for Women at Higher Risk. (Medscape)

    Letter, Comment:

    Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom

    Letter, Reply:

    Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdom—Reply.

    • Cancer prevention and screening in a BRCA2-positive male to female transgender patient.
    • Li JZ, Tu HYV, Avram R, Pinthus J, Bordeleau L, Hodgson N.
    • Breast J. 2018 Nov;24(6):1112-1113. doi: 10.1111/tbj.13096. Epub 2018 Jul 23.
    • Commentary
    • Breast cancer screening in young women.
    • Desreux JAC.
    • Eur J Obstet Gynecol Reprod Biol. 2018 Nov;230:208-211. doi: 10.1016/j.ejogrb.2018.05.018. Epub 2018 May 24.
    • Review
    • Survival of Women With Type I and II Epithelial Ovarian Cancer Detected by Ultrasound Screening.
    • van Nagell JR Jr, Burgess BT, Miller RW, Baldwin L, DeSimone CP, Ueland FR, Huang B, Chen Q, Kryscio RJ, Pavlik EJ.
    • Obstet Gynecol. 2018 Nov;132(5):1091-1100. doi: 10.1097/AOG.0000000000002921.

    Related:

    Editorial, Research news:

    Ultrasound Screening for Ovarian Cancer: Are We There Yet?

    • Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition.
    • Jatoi I.
    • Eur J Breast Health. 2018 Oct 1;14(4):189-193. doi: 10.5152/ejbh.2018.4324. eCollection 2018 Oct.

    Related:

    Letter, Review:

    What The Surgeons Should Know About The Bilateral Prophylactic Mastectomy in BRCA Mutation Carriers.

    • Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review.
    • Petelin L, Trainer AH, Mitchell G, Liew D, James PA.
    • Genet Med. 2018 Oct;20(10):1145-1156. doi: 10.1038/gim.2017.255. Epub 2018 Jan 11.
    • Review
    • Comparison of background parenchymal enhancement and fibroglandular density at breast magnetic resonance
    • Grubstein A, Rapson Y, Benzaquen O, Rozenblatt S, Gadiel I, Atar E, Yerushalmi R, Cohen MJ.
    • Clin Imaging. 2018 Sep - Oct;51:347-351. doi: 10.1016/j.clinimag.2018.06.010. Epub 2018 Jun 30.
    • Factors associated with breast MRI use among women with a family history of breast cancer.
    • White MC, Soman A, Weinberg CR, Rodriguez JL, Sabatino SA, Peipins LA, DeRoo L, Nichols HB, Hodgson ME, Sandler DP.
    • Breast J. 2018 Sep;24(5):764-771. doi: 10.1111/tbj.13063. Epub 2018 May 20.
    • Imaging Phenotypes in Women at High Risk for Breast Cancer on Mammography, Ultrasound, and Magnetic Resonance Imaging Using the Fifth Edition of the Breast Imaging Reporting and Data System.
    • Marino MA, Riedl CC, Bernathova M, Bernhart C, A T Baltzer P, Helbich TH, Pinker K.
    • Eur J Radiol. 2018 Sep;106:150-159. doi: 10.1016/j.ejrad.2018.07.026. Epub 2018 Jul 30.
    • The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI.
    • Vreemann S, van Zelst JCM, Schlooz-Vries M, Bult P, Hoogerbrugge N, Karssemeijer N, Gubern-Mérida A, Mann RM.
    • Breast Cancer Res. 2018 Aug 3;20(1):84. doi: 10.1186/s13058-018-1019-6.
    • Successful Repatriation of Breast Cancer Surveillance for High-Risk Women to the UK National Health Service Breast Screening Programme.
    • McVeigh TP, Wiggins J, Ward S, Kemp Z, George AJ.
    • Clin Breast Cancer. 2018 Aug;18(4):282-288. doi: 10.1016/j.clbc.2017.10.015. Epub 2017 Oct 28.
    • "Guys Don't Have Breasts": The Lived Experience of Men Who Have BRCA Gene Mutations and Are at Risk for Male Breast Cancer.
    • Skop M, Lorentz J, Jassi M, Vesprini D, Einstein G.
    • Am J Mens Health. 2018 Jul;12(4):961-972. doi: 10.1177/1557988317753241. Epub 2018 Feb 5.
    • Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations.
    • Kearton S, Wills K, Bunting M, Blomfield P, James PA, Burke J.
    • Fam Cancer. 2018 Jul;17(3):333-344. doi: 10.1007/s10689-017-0047-1.
    • Geographic Variation in Postoperative Imaging for Low-Risk Breast Cancer.
    • Franc BL, Copeland TP, Thombley R, Park M, Marafino B, Dean ML, Boscardin WJ, Rugo HS, Seidenwurm D, Sharma B, Johnston SR, Dudley RA.
    • J Natl Compr Canc Netw. 2018 Jul;16(7):829-837. doi: 10.6004/jnccn.2018.7024.
    • The frequency of missed breast cancers in women participating in a high-risk MRI screening program.
    • Vreemann S, Gubern-Merida A, Lardenoije S, Bult P, Karssemeijer N, Pinker K, Mann RM.
    • Breast Cancer Res Treat. 2018 Jun;169(2):323-331. doi: 10.1007/s10549-018-4688-z. Epub 2018 Jan 31.
    • Recommendations on prevention and screening for breast cancer in Hong Kong.
    • Lam TH, Wong KH, Chan KK, Chan MC, Chao DV, Cheung AN, Fan CY, Ho J, Hui EP, Lam KO, Law CK, Law WL, Loong HH, Ngan RK, Tsang TH, Wong MC, Yeung RM, Ying AC, Ching R.
    • Hong Kong Med J. 2018 Jun;24(3):298-306. doi: 10.12809/hkmj177037.
    • Mammographic density changes in surgical weight loss-an indication for personalized screening.
    • Partain N, Mokdad A, Puzziferri N, Porembka J, Seiler S, Christie A, Farr D, Rivers A, Marilyn Leitch A, Wooldridge R, Huth J, Rao R.
    • BMC Med Imaging. 2018 May 9;18(1):10. doi: 10.1186/s12880-017-0242-4.
    • Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort.
    • Braithwaite D, Miglioretti DL, Zhu W, Demb J, Trentham-Dietz A, Sprague B, Tice JA, Onega T, Henderson LM, Buist DSM, Ziv E, Walter LC, Kerlikowske K; Breast Cancer Surveillance Consortium.
    • JAMA Intern Med. 2018 Apr 1;178(4):494-501. doi: 10.1001/jamainternmed.2017.8642.

    Related:

    Research news:

    Older women with a family history of breast cancer face increased risk of the disease.

    • Prospective blinded surveillance screening of Swedish women with increased hereditary risk of breast cancer.
    • Liljegren A, von Wachenfeldt A, Azavedo E, Eloranta S, Grundström H, Ståhlbom AK, Sundbom A, Sundén P, Svane G, Ulitzsch D, Arver B.
    • Breast Cancer Res Treat. 2018 Apr;168(3):655-666. doi: 10.1007/s10549-017-4639-0. Epub 2018 Jan 9.
    • The Assessment of Background Parenchymal Enhancement (BPE) in a High-Risk Population: What Causes BPE?
    • You C, Kaiser AK, Baltzer P, Krammer J, Gu Y, Peng W, Schönberg SO, Kaiser CG.
    • Transl Oncol. 2018 Apr;11(2):243-249. doi: 10.1016/j.tranon.2017.12.006. Epub 2018 Jan 28.
    • Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision.
    • Lewis KE, Lu KH, Klimczak AM, Mok SC.
    • Cancers (Basel). 2018 Feb 21;10(2). pii: E57. doi: 10.3390/cancers10020057.
    • Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement.
    • US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, Doubeni CA, Epling JW Jr, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Tseng CW.
    • JAMA. 2018 Feb 13;319(6):588-594. doi: 10.1001/jama.2017.21926.

    Related:

    Evidence Report, Review:

    Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force

    Editorial: Screening for Ovarian Cancer in Asymptomatic Women (JAMA)

    Editorial: The Yet Unrealized Promise of Ovarian Cancer Screening (JAMA Oncology)

    Editorial: Is There a Future for Ovarian Cancer Screening? (JAMA Internal Medicine)

    JAMA Patient Page: Screening for Ovarian Cancer (JAMA)

    Press: 'No' to Ovarian Cancer Screening: Harms Outweigh Benefits. (Medscape)

    • Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    • Henderson JT, Webber EM, Sawaya GF.
    • JAMA. 2018 Feb 13;319(6):595-606. doi: 10.1001/jama.2017.21421.

    Related:

    Recommendation Statement:

    Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement.

    Editorial: Screening for Ovarian Cancer in Asymptomatic Women (JAMA)

    Editorial: The Yet Unrealized Promise of Ovarian Cancer Screening (JAMA Oncology)

    Editorial: Is There a Future for Ovarian Cancer Screening? (JAMA Internal Medicine)

    JAMA Patient Page: Screening for Ovarian Cancer (JAMA)

    Press: 'No' to Ovarian Cancer Screening: Harms Outweigh Benefits. (Medscape)

    • Should biannual MRIs replace annual mammograms in high-risk women?
    • [No author given]
    • FORCE. XRAYS. 2018 Feb 1.

    Related:

    Press: Biannual MRI Better Than Annual Mammogram at Detecting Breast Cancer in High-risk Women, Study Finds. (Breast Cancer News)

    Press: For women with genetic risk, semi-annual MRI beats mammograms. (ScienceDaily)

    • Breast tissue density change after oophorectomy in BRCA mutation carrier patients using visual and volumetric analysis.
    • Lecler A, Dunant A, Delaloge S, Wehrer D, Moussa T, Caron O, Balleyguier C.
    • Br J Radiol. 2018 Feb;91(1083):20170163. doi: 10.1259/bjr.20170163. Epub 2018 Jan 5.
    • Mammography screening: A major issue in medicine.
    • Autier P, Boniol M.
    • Eur J Cancer. 2018 Feb;90:34-62. doi: 10.1016/j.ejca.2017.11.002. Epub 2017 Dec 20.
    • Review
    • Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the BRCA Mutation and Other Women at Increased Risk.
    • Vreemann S, Gubern-Mérida A, Schlooz-Vries MS, Bult P, van Gils CH, Hoogerbrugge N, Karssemeijer N, Mann RM.
    • Radiology. 2018 Feb;286(2):443-451. doi: 10.1148/radiol.2017170458. Epub 2017 Oct 16.
    • Factors associated with false positive results on screening mammography in a population of predominantly Hispanic women.
    • McGuinness JE, Ueng W, Trivedi MS, Yi HS, David R, Vanegas A, Vargas J, Sandoval R, Kukafka R, Crew KD.
    • Cancer Epidemiol Biomarkers Prev. 2018 Jan 30. pii: cebp.0009.2017. doi: 10.1158/1055-9965.EPI-17-0009. [Epub ahead of print]
    • Biannual MRI Better Than Annual Mammogram at Detecting Breast Cancer in High-risk Women, Study Finds.
    • Inacio, P.
    • Breast Cancer News. 2018 Jan 5.

    Related:

    Research News: Should biannual MRIs replace annual mammograms in high-risk women? (FORCE, XRAYS)

    • The role of screening MRI in the era of next generation sequencing and moderate-risk genetic mutations.
    • Macklin S, Gass J, Mitri G, Atwal PS, Hines S.
    • Fam Cancer. 2018 Jan;17(1):167-173. doi: 10.1007/s10689-017-0007-9.
    • Review
    • Surveillance report 2018 – Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (2013) NICE guideline CG164 [Internet].
    • NICE Surveillance programme project team: Nolan K, Allaby M, McFarlane E, Murray A.
    • London: National Institute for Health and Care Excellence (UK); 2018 Jan.

    • Abnormal Findings Detected by Multi-modality Breast Imaging and Biopsy Results in a High-risk Clinic.
    • Laitman Y, Feldman DM, Sklair-Levy M, Yosepovich A, Barshack-Nakar I, Brodsky M, Halshtok O, Shalmon A, Gotlieb M, Friedman E.
    • Clin Breast Cancer. 2017 Dec 11. pii: S1526-8209(17)30559-1. doi: 10.1016/j.clbc.2017.12.005. [Epub ahead of print]
    • For women with genetic risk, semi-annual MRI beats mammograms.
    • [No author given.]
    • ScienceDaily. 2017 Dec 11.

    Related:

    Research News: Should biannual MRIs replace annual mammograms in high-risk women? (FORCE, XRAYS)

    • No evidence of excessive cancer screening in female noncarriers from BRCA1/2 mutation-positive families.
    • Guedaoura S, Pelletier S, Foulkes WD, Hamet P, Simard J, Wong N, El Haffaf Z, Chiquette J, Dorval M.
    • Curr Oncol. 2017 Dec;24(6):352-359. doi: 10.3747/co.24.3759. Epub 2017 Dec 20.
    • Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study.
    • Cortesi L, De Matteis E, Toss A, Marchi I, Medici V, Contu G, Xholli A, Grandi G, Cagnacci A, Federico M.
    • Oncology. [2017 Dec;]93(6):377-386. doi: 10.1159/000479155. Epub 2017 Aug 26.
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. Clinical Management of Carriers of BRCA Pathogenic Variants.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • A qualitative study on Singaporean women's views towards breast cancer screening and Single Nucleotide Polymorphisms (SNPs) gene testing to guide personalised screening strategies.
    • Wong XY, Chong KJ, van Til JA, Wee HL.
    • BMC Cancer. 2017 Nov 21;17(1):776. doi: 10.1186/s12885-017-3781-8.
    • Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography.
    • van Zelst JCM, Mus RDM, Woldringh G, Rutten MJCM, Bult P, Vreemann S, de Jong M, Karssemeijer N, Hoogerbrugge N, Mann RM.
    • Radiology. 2017 Nov;285(2):376-388. doi: 10.1148/radiol.2017161218. Epub 2017 Jun 13.
    • Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations.
    • Ha SM, Chae EY, Cha JH, Kim HH, Shin HJ, Choi WJ.
    • AJR Am J Roentgenol. 2017 Oct;209(4):920-928. doi: 10.2214/AJR.16.16957. Epub 2017 Aug 10.
    • Deep learning in breast cancer risk assessment: evaluation of convolutional neural networks on a clinical dataset of full-field digital mammograms.
    • Li H, Giger ML, Huynh BQ, Antropova NO.
    • J Med Imaging (Bellingham). 2017 Oct;4(4):041304. doi: 10.1117/1.JMI.4.4.041304. Epub 2017 Sep 13.
    • An Abbreviated Protocol for High-risk Screening Breast Magnetic Resonance Imaging: Impact on Performance Metrics and BI-RADS Assessment.
    • Panigrahi B, Mullen L, Falomo E, Panigrahi B, Harvey S.
    • Acad Radiol. 2017 Sep;24(9):1132-1138. doi: 10.1016/j.acra.2017.03.014. Epub 2017 May 11.
    • Screening Mammography for Women in Their 40s: The Potential Impact of the American Cancer Society and U.S. Preventive Services Task Force Breast Cancer Screening Recommendations.
    • Pitman JA, McGinty GB, Soman RR, Drotman MB, Reichman MB, Arleo EK.
    • AJR Am J Roentgenol. 2017 Sep;209(3):697-702. doi: 10.2214/AJR.16.17759. Epub 2017 May 15.
    • Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk.
    • Committee on Gynecologic Practice, Society of Gynecologic Oncology.
    • Obstet Gynecol. 2017 Sep;130(3):e146-e149. doi: 10.1097/AOG.0000000000002299.

    Related:

    Summary:

    Committee Opinion No. 716 Summary: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk.

    • MRI surveillance for women with dense breasts and a previous breast cancer and/or high risk lesion.
    • Nadler M, Al-Attar H, Warner E, Martel AL, Balasingham S, Zhang L, Lipton JH, Curpen B.
    • Breast. 2017 Aug;34:77-82. doi: 10.1016/j.breast.2017.04.005. Epub 2017 May 18.
    • History, development and future of cancer screening in Australia.
    • Olver IN, Roder D.
    • Public Health Res Pract. 2017 Jul 26;27(3). pii: 2731725. doi: 10.17061/phrp2731725.
    • Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
    • Skates SJ, Greene MH, Buys SS, Mai PL, Brown PH, Piedmonte M, Rodriguez GC, Schorge JO, Sherman M, Daly MB, Rutherford TJ, Brewster WR, O'Malley DM, Partridge EE, Boggess J, Drescher CW, Isaacs C, Berchuck A, Domchek SM, Davidson SA, Edwards RP, Elg SA, Wakeley K, Phillips KA, Armstrong DK, Horowitz IR, Fabian CJ, Walker J, Sluss PM, Welch WR, Minasian L, Horick N, Kasten CH, Nayfield S, Alberts DS, Finkelstein DM, Lu K.
    • Clin Cancer Res. 2017 Jul 15;23(14):3628-3637. doi: 10.1158/1078-0432.CCR-15-2750. Epub 2017 Jan 31.
    • Ductal Carcinoma in situ Detected during Prospective MR Imaging Screening of a Woman with a BRCA2 Mutation: The First Case Report in Japan.
    • Tozaki M, Nakamura S, Kitagawa D, Iwase T, Horii R, Akiyama F, Arai M.
    • Magn Reson Med Sci. 2017 Jul 10;16(3):265-269. doi: 10.2463/mrms.cr.2016-0090. Epub 2017 Jan 13.
    • BRCA-associated Cancers: Role of Imaging in Screening, Diagnosis, and Management.
    • Lee MV, Katabathina VS, Bowerson ML, Mityul MI, Shetty AS, Elsayes KM, Balachandran A, Bhosale PR, McCullough AE, Menias CO.
    • Radiographics. 2017 Jul-Aug;37(4):1005-1023. doi: 10.1148/rg.2017160144. Epub 2017 May 26.
    • Review
    • Managing hereditary breast cancer risk in women with and without ovarian cancer.
    • Peters ML, Garber JE, Tung N.
    • Gynecol Oncol. 2017 Jul;146(1):205-214. doi: 10.1016/j.ygyno.2017.04.013. Epub 2017 Apr 25.
    • Review
    • Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women.
    • [No authors listed]
    • Obstet Gynecol. 2017 Jul;130(1):e1-e16. doi: 10.1097/AOG.0000000000002158.

    Related:

    Summary:

    Practice Bulletin No. 179 Summary: Breast Cancer Risk Assessment and Screening in Average-Risk Women.

    • Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
    • Krammer J, Pinker-Domenig K, Robson ME, Gönen M, Bernard-Davila B, Morris EA, Mangino DA, Jochelson MS.
    • Breast Cancer Res Treat. 2017 Jun;163(3):565-571. doi: 10.1007/s10549-017-4198-4. Epub 2017 Mar 25.
    • Cumulative risk of breast cancer screening outcomes according to the presence of previous benign breast disease and family history of breast cancer: supporting personalised screening.
    • Román M, Quintana MJ, Ferrer J, Sala M, Castells X.
    • Br J Cancer. 2017 May 23;116(11):1480-1485. doi: 10.1038/bjc.2017.107. Epub 2017 Apr 20.
    • Imaging of Hereditary Tumors of the Female Genital System.
    • Rothan SM, Menias CO, ElGuindy YM, Jensen CT, Shaaban A, Bhosale P, Lee MV, Katabathina VS, Elsayes KM.
    • J Comput Assist Tomogr. 2017 May/Jun;41(3):364-375. doi: 10.1097/RCT.0000000000000558.
    • Review
    • Chronic Pancreatitis-Like Change in BRCA2 Mutation Carriers.
    • Mizrahi M, Tseng JF, Wong D, Tung N, Eskander MF, Berzin TM, Pleskow DK, Sawhney MS.
    • Pancreas. 2017 May/Jun;46(5):679-683. doi: 10.1097/MPA.0000000000000814.
    • Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
    • McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, Foulkes WD, Neuhausen SL, Kotsopoulos J, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.
    • Gynecol Oncol. 2017 May;145(2):346-351. doi: 10.1016/j.ygyno.2017.02.032. Epub 2017 Mar 14.
    • Breast Cancer Risk Assessment Models and High-Risk Screening.
    • Barke LD, Freivogel ME.
    • Radiol Clin North Am. 2017 May;55(3):457-474. doi: 10.1016/j.rcl.2016.12.013.
    • Review
    • Screening Breast MRI Outcomes in Routine Clinical Practice: Comparison to BI-RADS Benchmarks.
    • Strigel RM, Rollenhagen J, Burnside ES, Elezaby M, Fowler AM, Kelcz F, Salkowski L, DeMartini WB.
    • Acad Radiol. 2017 Apr;24(4):411-417. doi: 10.1016/j.acra.2016.10.014. Epub 2016 Dec 13.
    • Breast cancer screening of pregnant and breastfeeding women with BRCA mutations.
    • Carmichael H, Matsen C, Freer P, Kohlmann W, Stein M, Buys SS, Colonna S.
    • Breast Cancer Res Treat. 2017 Apr;162(2):225-230. doi: 10.1007/s10549-017-4122-y. Epub 2017 Jan 30.
    • Review

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Article request

    • Increased Identification of Candidates for High-Risk Breast Cancer Screening Through Expanded Genetic Testing.
    • Rosenthal ET, Evans B, Kidd J, Brown K, Gorringe H, van Orman M, Manley S.
    • J Am Coll Radiol. 2017 Apr;14(4):561-568. doi: 10.1016/j.jacr.2016.10.003. Epub 2016 Dec 20.
    • Early-onset primary peritoneal carcinoma from atypical cells after risk-reducing salpingo-oophorectomy for BRCA2 mutation carrier: a case report.
    • Shimizu H, Ishikawa T, Iitsuka C, Homma M, Takimoto M, Sekizawa A.
    • Int Cancer Conf J. 2017 Mar 21;6(3):104-108. doi: 10.1007/s13691-017-0287-9. eCollection 2017 Jul.
    • Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer.
    • Huzarski T, Górecka-Szyld B, Huzarska J, Psut-Muszyńska G, Wilk G, Sibilski R, Cybulski C, Kozak-Klonowska B, Siołek M, Kilar E, Czudowska D, Janiszewska H, Godlewski D, Mackiewicz A, Jarkiewicz-Tretyn J, Szabo-Moskal J, Gronwald J, Lubiński J, Narod SA; Polish Hereditary Breast Cancer Study Group.
    • Hered Cancer Clin Pract. 2017 Mar 1;15:4. doi: 10.1186/s13053-017-0064-y. eCollection 2017.
    • Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay.
    • Baert A, Depuydt J, Van Maerken T, Poppe B, Malfait F, Van Damme T, De Nobele S, Perletti G, De Leeneer K, Claes KB, Vral A.
    • Oncol Rep. 2017 Mar;37(3):1379-1386. doi: 10.3892/or.2017.5407. Epub 2017 Jan 25.
    • Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.
    • Shieh Y, Eklund M, Madlensky L, Sawyer SD, Thompson CK, Stover Fiscalini A, Ziv E, Van't Veer LJ, Esserman LJ, Tice JA; Athena Breast Health Network Investigators.
    • J Natl Cancer Inst. 2017 Jan 27;109(5). pii: djw290. doi: 10.1093/jnci/djw290. Print 2017 Jan.
    • Review

    Related:

    Editorial:

    The Complexity of Achieving the Promise of Precision Breast Cancer Screening.

    • Do women change their breast cancer mammogram screening behaviour after BRCA1/2 testing?
    • Larouche G, Chiquette J, Pelletier S, Simard J, Dorval M.
    • Fam Cancer. 2017 Jan;16(1):35-40. doi: 10.1007/s10689-016-9920-6.
    • Breast Cancer Epidemiology, Prevention, and Screening.
    • Winters S, Martin C, Murphy D, Shokar NK.
    • Prog Mol Biol Transl Sci. 2017;151:1-32. doi: 10.1016/bs.pmbts.2017.07.002. Epub 2017 Oct 10.
    • Review
    • Breast Cancer Screening for High-Risk Patients of Different Ages and Risk - Which Modality Is Most Effective?
    • Wellings E, Vassiliades L, Abdalla R.
    • Cureus. 2016 Dec 28;8(12):e945. doi: 10.7759/cureus.945.
    • Recommendations for breast imaging follow-up of women with a previous history of breast cancer: position paper from the Italian Group for Mammography Screening (GISMa) and the Italian College of Breast Radiologists (ICBR) by SIRM.
    • Bucchi L, Belli P, Benelli E, Bernardi D, Brancato B, Calabrese M, Carbonaro LA, Caumo F, Cavallo-Marincola B, Clauser P, Fedato C, Frigerio A, Galli V, Giordano L, Golinelli P, Mariscotti G, Martincich L, Montemezzi S, Morrone D, Naldoni C, Paduos A, Panizza P, Pediconi F, Querci F, Rizzo A, Saguatti G, Tagliafico A, Trimboli RM, Zuiani C, Sardanelli F.
    • Radiol Med. 2016 Dec;121(12):891-896. Epub 2016 Sep 6.
    • Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 Mutation Carriers.
    • Larouche G, Chiquette J, Plante M, Pelletier S, Simard J, Dorval M.
    • Can Assoc Radiol J. 2016 Nov;67(4):308-312. doi: 10.1016/j.carj.2015.12.003. Epub 2016 Jun 16.
    • Mammography and MRI for screening women who underwent chest radiation therapy (lymphoma survivors): recommendations for surveillance from the Italian College of Breast Radiologists by SIRM.
    • Mariscotti G, Belli P, Bernardi D, Brancato B, Calabrese M, Carbonaro LA, Cavallo-Marincola B, Caumo F, Clauser P, Martinchich L, Montemezzi S, Panizza P, Pediconi F, Tagliafico A, Trimboli RM, Zuiani C, Sardanelli F.
    • Radiol Med. 2016 Nov;121(11):834-837. Epub 2016 Jul 12.
    • Management of women with a hereditary predisposition for breast cancer.
    • Jatoi I, Benson JR.
    • Future Oncol. 2016 Oct;12(19):2277-88. doi: 10.2217/fon-2016-0186. Epub 2016 Jul 7.
    • Review
    • Automated Breast Volumetric Sonography Compared with Magnetic Resonance Imaging in Jewish BRCA 1/2 Mutation Carriers.
    • Halshtok Neiman O, Erlich Z, Friedman E, Rundstein A, Shalmon A, Servadio Y, Sklair Levy M.
    • Isr Med Assoc J. 2016 Oct;18(10):609-612.
    • Breast Cancers Detected at Screening MR Imaging and Mammography in Patients at High Risk: Method of Detection Reflects Tumor Histopathologic Results.
    • Sung JS, Stamler S, Brooks J, Kaplan J, Huang T, Dershaw DD, Lee CH, Morris EA, Comstock CE.
    • Radiology. 2016 Sep;280(3):716-22. doi: 10.1148/radiol.2016151419. Epub 2016 Apr 20.
    • Comparative effectiveness of breast MRI and mammography in screening young women with elevated risk of developing breast cancer: a retrospective cohort study.
    • Narayan AK, Visvanathan K, Harvey SC.
    • Breast Cancer Res Treat. 2016 Aug;158(3):583-9. doi: 10.1007/s10549-016-3912-y. Epub 2016 Jul 21.
    • Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline.
    • van Os NJ, Roeleveld N, Weemaes CM, Jongmans MC, Janssens GO, Taylor AM, Hoogerbrugge N, Willemsen MA.
    • Clin Genet. 2016 Aug;90(2):105-17. doi: 10.1111/cge.12710. Epub 2016 Jan 20.
    • Review

    Related:

    Comments on NSGC Discussion Forum Cancer SIG:

    Subject: Article request

    • Mammographic screening in BRCA1 mutation carriers postponed until age 40: Evaluation of benefits, costs and radiation risks using models.
    • Obdeijn IM, Heijnsdijk EA, Hunink MG, Tilanus-Linthorst MM, de Koning HJ.
    • Eur J Cancer. 2016 Aug;63:135-42. doi: 10.1016/j.ejca.2016.05.012. Epub 2016 Jun 15.
    • Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study.
    • Evans DG, Astley S, Stavrinos P, Harkness E, Donnelly LS, Dawe S, Jacob I, Harvie M, Cuzick J, Brentnall A, Wilson M, Harrison F, Payne K, Howell A.
    • Southampton (UK): NIHR Journals Library; 2016 Aug.
    • An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers.
    • Madorsky-Feldman D, Sklair-Levy M, Perri T, Laitman Y, Paluch-Shimon S, Schmutzler R, Rhiem K, Lester J, Karlan BY, Singer CF, Van Maerken T, Claes K, Brunet J, Izquierdo A, Teulé A, Lee JW, Kim SW, Arun B, Jakubowska A, Lubinski J, Tucker K, Poplawski NK, Varesco L, Bonelli LA, Buys SS, Mitchell G, Tischkowitz M, Gerdes AM, Seynaeve C, Robson M, Kwong A, Tung N, Tessa N, Domchek SM, Godwin AK, Rantala J, Arver B, Friedman E.
    • Breast Cancer Res Treat. 2016 Jun;157(2):319-27. doi: 10.1007/s10549-016-3805-0. Epub 2016 Apr 27.
    • The value of breast MRI in high-risk patients with newly diagnosed breast cancer to exclude invasive disease in the contralateral prophylactic mastectomy: Is there a role to choose wisely patients for sentinel node biopsy?
    • Freitas V, Crystal P, Kulkarni SR, Ghai S, Bukhanov K, Escallon J, Scaranelo AM.
    • Cancer Med. 2016 Jun;5(6):1031-6. doi: 10.1002/cam4.663. Epub 2016 Mar 18.
    • Intensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortality.
    • Evans DG, Harkness EF, Howell A, Wilson M, Hurley E, Holmen MM, Tharmaratnam KU, Hagen AI, Lim Y, Maxwell AJ, Moller P.
    • Hered Cancer Clin Pract. 2016 Apr 14;14:8. doi: 10.1186/s13053-016-0048-3. eCollection 2016.
    • Towards personalized screening: Cumulative risk of breast cancer screening outcomes in women with and without a first-degree relative with a history of breast cancer.
    • Ripping TM, Hubbard RA, Otten JD, den Heeten GJ, Verbeek AL, Broeders MJ.
    • Int J Cancer. 2016 Apr 1;138(7):1619-25. doi: 10.1002/ijc.29912. Epub 2015 Nov 20.
    • The Management of Breast Cancer Detected by Reduction Mammaplasty.
    • Carlson GW.
    • Clin Plast Surg. 2016 Apr;43(2):341-7. doi: 10.1016/j.cps.2015.12.001. Epub 2016 Jan 26.
    • Review
    • The Problem of Mammographic Breast Density - The Position of the DEGUM Working Group on Breast Ultrasound.
    • Mueller-Schimpfle MP, Brandenbusch VC, Degenhardt F, Duda V, Madjar H, Mundinger A, Rathmann R, Hahn M.
    • Ultraschall Med. 2016 Apr;37(2):170-175. Epub 2016 Feb 16.
    • Review
    • Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis.
    • Phi XA, Saadatmand S, De Bock GH, Warner E, Sardanelli F, Leach MO, Riedl CC, Trop I, Hooning MJ, Mandel R, Santoro F, Kwan-Lim G, Helbich TH, Tilanus-Linthorst MM, van den Heuvel ER, Houssami N.
    • Br J Cancer. 2016 Mar 15;114(6):631-637. doi: 10.1038/bjc.2016.32. Epub 2016 Feb 23.
    • Meta-Analysis
    • Assessment of Background Parenchymal Enhancement and Lesion Kinetics in Breast MRI of BRCA 1/2 Mutation Carriers Compared to Matched Controls Using Quantitative Kinetic Analysis.
    • Lewin AA, Gene Kim S, Babb JS, Melsaether AN, McKellop J, Moccaldi M, Klautau Leite AP, Moy L.
    • Acad Radiol. 2016 Mar;23(3):358-67. doi: 10.1016/j.acra.2015.11.011. Epub 2016 Jan 7.
    • No strong evidence for increased risk of breast cancer 8-26 years after multiple mammograms in their 30s in females at moderate and high familial risk.
    • Evans DG, Kotre CJ, Harkness E, Wilson M, Maxwell AJ, Howell A.
    • Br J Radiol. 2016 Mar;89(1059):20150960. doi: 10.1259/bjr.20150960. Epub 2016 Jan 21.
    • Influence of Personal Exposure to the Cancer of a Loved One on the Breast Cancer Prevention Decisions of High Risk Women.
    • Padamsee TJ, Muraveva A, Wills C, Yee L, Paskett E.
    • Cancer Epidemiol Biomarkers Prev. 2016 Mar;25(3):561. 40th Annual (2016) ASPO meeting. doi: 10.1158/1055-9965.EPI-16-0090.
    • Conference abstract
    • Triple-Negative versus Non-Triple-Negative Breast Cancers in High-Risk Women: Phenotype Features and Survival from the HIBCRIT-1 MRI-Including Screening Study.
    • Podo F, Santoro F, Di Leo G, Manoukian S, de Giacomi C, Corcione S, Cortesi L, Carbonaro LA, Trimboli RM, Cilotti A, Preda L, Bonanni B, Pensabene M, Martincich L, Savarese A, Contegiacomo A, Sardanelli F.
    • Clin Cancer Res. 2016 Feb 15;22(4):895-904. doi: 10.1158/1078-0432.CCR-15-0459. Epub 2015 Oct 26.
    • Diagnostic Performance of MR-guided Vacuum-Assisted Breast Biopsy: 8 Years of Experience.
    • Ferré R, Ianculescu V, Ciolovan L, Mathieu MC, Uzan C, Canale S, Delaloge S, Dromain C, Balleyguier C.
    • Breast J. 2016 Jan-Feb;22(1):83-9. doi: 10.1111/tbj.12519. Epub 2015 Oct 28.
    • UC Launches Framingham-Like Study to Inform Personalized Breast Cancer Screening Guidelines.
    • Ray T.
    • GenomeWeb. 2015 Oct 26.
    • News
    • Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).
    • Saadatmand S, Obdeijn IM, Rutgers EJ, Oosterwijk JC, Tollenaar RA, Woldringh GH, Bergers E, Verhoef C, Heijnsdijk EA, Hooning MJ, de Koning HJ, Tilanus-Linthorst MM.
    • Int J Cancer. 2015 Oct 1;137(7):1729-1738. doi: 10.1002/ijc.29534. Epub 2015 Apr 17.
    • Moreton Lecture: Imaging in the Age of Precision Medicine.
    • Thrall JH.
    • J Am Coll Radiol. 2015 Oct;12(10):1106-11. doi: 10.1016/j.jacr.2015.06.003. Epub 2015 Aug 22.
    • Imaging surveillance programs for women at high breast cancer risk in Europe: Are women from ethnic minority groups adequately included? (Review).
    • Belkić K, Cohen M, Wilczek B, Andersson S, Berman AH, Márquez M, Vukojević V, Mints M.
    • Int J Oncol. 2015 Sep;47(3):817-39. doi: 10.3892/ijo.2015.3063. Epub 2015 Jun 26.
    • Review
    • Can the breast screening appointment be used to provide risk assessment and prevention advice?
    • Evans DG, Howell A.
    • Breast Cancer Res. 2015 Jul 9;17(1):84. doi: 10.1186/s13058-015-0595-y.
    • Tumour characteristics and survival in familial breast cancer prospectively diagnosed by annual mammography.
    • Møller P, Tharmaratnam K, Howell A, Stavrinos P, Sampson S, Wallace A, Maxwell AJ, Hagen AI, Evans DG.
    • Breast Cancer Res Treat. 2015 Jul;152(1):87-94. doi: 10.1007/s10549-015-3448-6. Epub 2015 Jun 3.
    • Breast Cancer Risk Reduction, Version 2.2015.
    • Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R.
    • J Natl Compr Canc Netw. 2015 Jul;13(7):880-915.
    • Practice guideline
    • Adjusting the frequency of mammography screening on the basis of genetic risk: Attitudes among women in the UK.
    • Meisel SF, Pashayan N, Rahman B, Side L, Fraser L, Gessler S, Lanceley A, Wardle J.
    • Breast. 2015 Jun;24(3):237-41. doi: 10.1016/j.breast.2015.02.001. Epub 2015 Feb 21.
    • Lipid and Metabolite Deregulation in the Breast Tissue of Women Carrying BRCA1 and BRCA2 Genetic Mutations.
    • Ramadan S, Arm J, Silcock J, Santamaria G, Buck J, Roy M, Leong KM, Lau P, Clark D, Malycha P, Mountford C.
    • Radiology. 2015 Jun;275(3):675-82. doi: 10.1148/radiol.15140967. Epub 2015 Mar 3.

    Related:

    Comment / Letter:

    Lipid and Metabolite Deregulation in BRCA1 and BRCA2 Genetic Mutations.

    • Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers.
    • Wu S, Weinstein SP, DeLeo MJ 3rd, Conant EF, Chen J, Domchek SM, Kontos D.
    • Breast Cancer Res. 2015 May 19;17(1):67. doi: 10.1186/s13058-015-0577-0.
    • Topol: Time to End Routine Mammography.
    • Eric J. Topol.
    • Medscape. 2015 May 6.
    • Screening magnetic resonance imaging recommendations and outcomes in patients at high risk for breast cancer.
    • Ehsani S, Strigel RM, Pettke E, Wilke L, Tevaarwerk AJ, DeMartini WB, Wisinski KB.
    • Breast J. 2015 May-Jun;21(3):246-53. doi: 10.1111/tbj.12396. Epub 2015 Mar 17.
    • Breast Self-examination Education for BRCA Mutation Carriers by Clinical Nurse Specialists.
    • Visser A, Bos WC, Prins JB, Hoogerbrugge N, van Laarhoven HW.
    • Clin Nurse Spec. 2015 May-Jun;29(3):E1-E7.
    • Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.
    • Riedl CC, Luft N, Bernhart C, Weber M, Bernathova M, Tea MK, Rudas M, Singer CF, Helbich TH.
    • J Clin Oncol. 2015 Apr 1;33(10):1128-35. doi: 10.1200/JCO.2014.56.8626. Epub 2015 Feb 23.
    • Breast MRI as an adjunct to mammography for breast cancer screening in high-risk patients: retrospective review.
    • Raikhlin A, Curpen B, Warner E, Betel C, Wright B, Jong R.
    • AJR Am J Roentgenol. 2015 Apr;204(4):889-97. doi: 10.2214/AJR.13.12264.
    • Breast MRI Fibroglandular Volume and Parenchymal Enhancement in BRCA1 and BRCA2 Mutation Carriers Before and Immediately After Risk-Reducing Salpingo-Oophorectomy.
    • DeLeo MJ 3rd, Domchek SM, Kontos D, Conant E, Chen J, Weinstein S.
    • AJR Am J Roentgenol. 2015 Mar;204(3):669-73. doi: 10.2214/AJR.13.12146.
    • Comparative effectiveness of combined digital mammography and tomosynthesis screening for women with dense breasts.
    • Lee CI, Cevik M, Alagoz O, Sprague BL, Tosteson AN, Miglioretti DL, Kerlikowske K, Stout NK, Jarvik JG, Ramsey SD, Lehman CD.
    • Radiology. 2015 Mar;274(3):772-80. doi: 10.1148/radiol.14141237. Epub 2014 Oct 28.
    • Personalized assessment and management of women at risk for breast cancer in North America.
    • Pruthi S, Heisey R, Bevers T.
    • Womens Health (Lond Engl). 2015 Mar;11(2):213-23; quiz 223-4. doi: 10.2217/whe.14.79.
    • Ultrasonographic characteristics and BI-RADS-US classification of BRCA1 mutation-associated breast cancer in Guangxi, China.
    • Li C, Liu J, Wang S, Chen Y, Yuan Z, Zeng J, Li Z.
    • Int J Clin Exp Med. 2015 Feb 15;8(2):2411-6. eCollection 2015.
    • Magnetic Resonance Imaging Improves Breast Screening Sensitivity in BRCA Mutation Carriers Age ≥ 50 Years: Evidence From an Individual Patient Data Meta-Analysis.
    • Phi XA, Houssami N, Obdeijn IM, Warner E, Sardanelli F, Leach MO, Riedl CC, Trop I, Tilanus-Linthorst MM, Mandel R, Santoro F, Kwan-Lim G, Helbich TH, de Koning HJ, Van den Heuvel ER, de Bock GH.
    • J Clin Oncol. 2015 Feb 1;33(4):349-56. doi: 10.1200/JCO.2014.56.6232. Epub 2014 Dec 22.
    • Intensified surveillance for early detection of breast cancer in high-risk patients.
    • Bick U.
    • Breast Care (Basel). 2015 Feb;10(1):13-20. doi: 10.1159/000375390.
    • A comprehensive approach to the identification and management of the BRCA patient.
    • Garcia C, Powell CB.
    • Obstet Gynecol Surv. 2015 Feb;70(2):131-43. doi: 10.1097/OGX.0000000000000156.
    • Review
    • Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: A national cohort study.
    • Saadatmand S, Vos JR, Hooning MJ, Oosterwijk JC, Koppert LB, de Bock GH, Ausems MG, van Asperen CJ, Aalfs CM, Gómez Garcia EB, Meijers-Heijboer H, Hoogerbrugge N, Piek M, Seynaeve C, Verhoef C, Rookus M, Tilanus-Linthorst MM; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON).
    • Int J Cancer. 2014 Dec 15;135(12):2940-9. doi: 10.1002/ijc.28941. Epub 2014 May 20.
    • Breast Cancer Following Ovarian Cancer in BRCA Mutation Carriers.
    • Gangi A, Cass I, Paik D, Barmparas G, Karlan B, Dang C, Li A, Walsh C, Rimel BJ, Amersi FF.
    • JAMA Surg. 2014 Dec 1;149(12):1306-1313. doi: 10.1001/jamasurg.2014.1081.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG:

    Subject: Breast cancer risk in ovarian cancer survivors

    Subject: BRCA+ ovarian ca dx- breast ca risk and outcomes

    Letter:

    Effect of Breast Cancer After Ovarian Cancer on Mortality for BRCA Mutation Carriers.

    Letter, Reply:

    Effect of Breast Cancer After Ovarian Cancer on Mortality for BRCA Mutation Carriers-Reply.

    • Breast Cancer in Male-to-Female Transsexuals: Use of Breast Imaging for Detection.
    • Maglione KD, Margolies L, Jaffer S, Szabo J, Schmidt H, Weltz C, Sonnenblick EB.
    • AJR Am J Roentgenol. 2014 Dec;203(6):W735-40. doi: 10.2214/AJR.14.12723.

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Cancer risks for transgender patient

    • Rate of contralateral prophylactic mastectomy is influenced by preoperative MRI recommendations.
    • Xia C, Schroeder MC, Weigel RJ, Sugg SL, Thomas A.
    • Ann Surg Oncol. 2014 Dec;21(13):4133-8. doi: 10.1245/s10434-014-3852-x. Epub 2014 Jun 17.
    • MRI screening of women with hereditary predisposition to breast cancer: diagnostic performance and survival analysis.
    • Tharmaratnam K, Hagen AI, Møller P.
    • Breast Cancer Res Treat. 2014 Dec;148(3):687-8. doi: 10.1007/s10549-014-3178-1. Epub 2014 Nov 15.

    Related:

    MRI breast screening in high-risk women: cancer detection and survival analysis.

    Comment, Reply:

    BCRT response to Moller.

    • BCRT response to Moller.
    • Evans DG.
    • Breast Cancer Res Treat. 2014 Dec;148(3):693. doi: 10.1007/s10549-014-3200-7.

    Related:

    MRI breast screening in high-risk women: cancer detection and survival analysis.

    Letter, Comment:

    MRI screening of women with hereditary predisposition to breast cancer: diagnostic performance and survival analysis.

    • The role of genome sequencing in personalized breast cancer prevention.
    • Sieh W, Rothstein JH, McGuire V, Whittemore AS.
    • Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2322-7. doi: 10.1158/1055-9965.EPI-14-0559.

    Related:

    Press: Genomic Sequencing More Efficient in Predicting Breast Cancer Risk Than Previously Thought. (AACR Newsroom)

    Blog: Cancer Genomics: Using Big Data to Advance Breast Cancer Risk Prediction. (Cancer Research Catalyst/AACR)

    Press: Here’s How Well Your Genes Can Predict Your Breast Cancer Risk. (Time | Health)

    • Screening and Nonsurgical Methods of Prevention for Women at High Risk for Breast Cancer.
    • Victoria Seewaldt
    • FORCE. Be Empowered Webinars. 2014 Oct 22.
    • Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk.
    • Ahern CH, Shih YC, Dong W, Parmigiani G, Shen Y.
    • Br J Cancer. 2014 Oct 14;111(8):1542-1551. doi: 10.1038/bjc.2014.458. Epub 2014 Aug 19.
    • MRI screening of women with hereditary predisposition to breast cancer: diagnostic performance and survival analysis.
    • Santoro F, Podo F, Sardanelli F.
    • Breast Cancer Res Treat. 2014 Oct;147(3):685-7. doi: 10.1007/s10549-014-3097-1. Epub 2014 Sep 2.
    • Letter, Comment

    Related:

    MRI breast screening in high-risk women: cancer detection and survival analysis.

    Reply, Comment:

    Response to Santoro et al.

    • Breast cancer risk in young women in the national breast screening programme: implications for applying NICE guidelines for additional screening and chemoprevention.
    • Evans DG, Brentnall AR, Harvie M, Dawe S, Sergeant JC, Stavrinos P, Astley S, Wilson M, Ainsworth J, Cuzick J, Buchan I, Donnelly LS, Howell A.
    • Cancer Prev Res (Phila). 2014 Oct;7(10):993-1001. doi: 10.1158/1940-6207.CAPR-14-0037. Epub 2014 Jul 21.
    • Contralateral Prophylactic Mastectomy in the American College of Radiology Imaging Network 6667 Trial: Effect of Breast MR Imaging Assessments and Patient Characteristics.
    • Rahbar H, Hanna LG, Gatsonis C, Mahoney MC, Schnall MD, DeMartini WB, Lehman CD.
    • Radiology. 2014 Oct;273(1):53-60. doi: 10.1148/radiol.14132029. Epub 2014 Jun 16.
    • Attitudes and compliance of clinical management after genetic testing for hereditary breast and ovarian cancer among high-risk Southern Chinese females with breast cancer history.
    • Kwong A, Chu AT, Wu CT, Tse DM.
    • Fam Cancer. 2014 Sep;13(3):423-30. doi: 10.1007/s10689-014-9706-7.
    • Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study.
    • Gierach GL, Li H, Loud JT, Greene MH, Chow CK, Lan L, Prindiville SA, Eng-Wong J, Soballe PW, Giambartolomei C, Mai PL, Galbo CE, Nichols K, Calzone KA, Olopade OI, Gail MH, Giger ML.
    • Breast Cancer Res. 2014;16(4):424. doi: 10.1186/PREACCEPT-1744229618121391. Epub 2014 Aug 23.
    • The additional cancer yield of clinical breast examination in screening of women at hereditary increased risk of breast cancer: a systematic review.
    • Roeke T, van Bommel AC, Gaillard-Hemmink MP, Hartgrink HH, Mesker WE, Tollenaar RA.
    • Breast Cancer Res Treat. 2014 Aug;147(1):15-23. doi: 10.1007/s10549-014-3074-8. Epub 2014 Aug 8.
    • Review
    • Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
    • Giannakeas V, Lubinski J, Gronwald J, Moller P, Armel S, Lynch HT, Foulkes WD, Kim-Sing C, Singer C, Neuhausen SL, Friedman E, Tung N, Senter L, Sun P, Narod SA.
    • Breast Cancer Res Treat. 2014 Aug;147(1):113-8. doi: 10.1007/s10549-014-3063-y. Epub 2014 Aug 1.
    • Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program.
    • Chiarelli AM, Prummel MV, Muradali D, Majpruz V, Horgan M, Carroll JC, Eisen A, Meschino WS, Shumak RS, Warner E, Rabeneck L.
    • J Clin Oncol. 2014 Jul 20;32(21):2224-30. doi: 10.1200/JCO.2013.52.8331. Epub 2014 Jun 16.

    Related:

    Editorial, Comment:

    How well does supplemental screening magnetic resonance imaging work in high-risk women?

    • Magnetic resonance imaging in patients with newly diagnosed breast cancer: A review of the literature.
    • Pilewskie M, King TA.
    • Cancer. 2014 Jul 15;120(14):2080-9. doi: 10.1002/cncr.28700. Epub 2014 Apr 18.
    • Applications for Breast Magnetic Resonance Imaging.
    • Pilewskie M, Morrow M.
    • Surg Oncol Clin N Am. 2014 Jul;23(3):431-449. doi: 10.1016/j.soc.2014.03.001. Epub 2014 Apr 18.
    • Review
    • Breast cancer screening using tomosynthesis in combination with digital mammography.
    • Friedewald SM, Rafferty EA, Rose SL, Durand MA, Plecha DM, Greenberg JS, Hayes MK, Copit DS, Carlson KL, Cink TM, Barke LD, Greer LN, Miller DP, Conant EF.
    • JAMA. 2014 Jun 25;311(24):2499-507. doi: 10.1001/jama.2014.6095.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG:

    Subject: 3D mammography

    News:

    Breast cancer: Improving cancer detection rates.

    Comment, Letter:

    Breast cancer screening with tomosynthesis and digital mammography.

    Comment, Editorial:

    Breast cancer screening: should tomosynthesis replace digital mammography?

    • MRI breast screening in high-risk women: cancer detection and survival analysis.
    • Evans DG, Kesavan N, Lim Y, Gadde S, Hurley E, Massat NJ, Maxwell AJ, Ingham S, Eeles R, Leach MO; MARIBS Group, Howell A, Duffy SW.
    • Breast Cancer Res Treat. 2014 Jun;145(3):663-72. doi: 10.1007/s10549-014-2931-9. Epub 2014 Apr 1.

    Related:

    See PubMed abstract for multiple related items.

    • Impact of familial risk and mammography screening on prognostic indicators of breast disease among women from the Ontario site of the Breast Cancer Family Registry.
    • Walker MJ, Mirea L, Cooper K, Nabavi M, Glendon G, Andrulis IL, Knight JA, O'Malley FP, Chiarelli AM.
    • Fam Cancer. 2014 Jun;13(2):163-72. doi: 10.1007/s10689-013-9689-9.
    • Social and Clinical Determinants of Contralateral Prophylactic Mastectomy.
    • Hawley ST, Jagsi R, Morrow M, Janz NK, Hamilton A, Graff JJ, Katz SJ.
    • JAMA Surg. 2014 Jun;149(6):582-9. doi: 10.1001/jamasurg.2013.5689.

    Related:

    Comment:

    Contralateral Prophylactic Mastectomy: An Opportunity for Shared Decision Making.

    • Short-term outcomes of the implementation of a computer-based breast cancer risk assessment program during screening mammography.
    • Ray D, Grumet S, Lagmay-Fuentes P, Jacob L, Terzo A, Puma A, Hwang S.
    • J Community Support Oncol. 2014 Jun;12(6):209-11.
    • The Genetic Testing Experience of BRCA-Positive Women: Deciding Between Surveillance and Surgery.
    • Hesse-Biber S.
    • Qual Health Res. 2014 Jun;24(6):773-789. Epub 2014 Apr 18.
    • Management of women at high risk of breast cancer.
    • Armstrong AC, Evans GD.
    • BMJ. 2014 Apr 28;348:g2756. doi: 10.1136/bmj.g2756.
    • Review
    • Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
    • Obdeijn IM, Winter-Warnars GA, Mann RM, Hooning MJ, Hunink MG, Tilanus-Linthorst MM.
    • Breast Cancer Res Treat. 2014 Apr;144(3):577-82. doi: 10.1007/s10549-014-2888-8. Epub 2014 Feb 25.
    • Disclosure Pattern and Follow-Up After the Molecular Diagnosis of BRCA/CHEK2 Mutations.
    • Kegelaers D, Merckx W, Odeurs P, van den Ende J, Blaumeiser B.
    • J Genet Couns. 2014 Apr;23(2):254-61. doi: 10.1007/s10897-013-9656-5. Epub 2013 Oct 11.
    • Diffusion-weighted imaging of the high-risk breast: Apparent diffusion coefficient values and their relationship to breast density.
    • O'Flynn EA, Wilson RM, Allen SD, Locke I, Scurr E, deSouza NM.
    • J Magn Reson Imaging. 2014 Apr;39(4):805-11. doi: 10.1002/jmri.24243. Epub 2013 Sep 13.
    • An alternative approach to selecting patients for high-risk screening with breast MRI.
    • Hollingsworth AB, Stough RG.
    • Breast J. 2014 Mar-Apr;20(2):192-7. doi: 10.1111/tbj.12242. Epub 2014 Jan 6.
    • Supplemental screening ultrasound increases cancer detection yield in BRCA1 and BRCA2 mutation carriers.
    • Bosse K, Graeser M, Goßmann A, Hackenbroch M, Schmutzler RK, Rhiem K.
    • Arch Gynecol Obstet. 2014 Mar;289(3):663-70. doi: 10.1007/s00404-013-3022-6. Epub 2013 Sep 18.
    • [Risk-adapted surveillance: focus on familial breast and ovarian cancer].
    • Rhiem K, Schmutzler RK.
    • Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014 Mar;57(3):307-11. doi: 10.1007/s00103-013-1910-3.
    • [Article in German]
    • Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer (FH02).
    • Evans DG, Thomas S, Caunt J, Roberts L, Howell A, Wilson M, Fox R, Sibbering DM, Moss S, Wallis MG, Eccles DM; FH02 study group, Duffy S.
    • Fam Cancer. 2014 Mar;13(1):13-21. doi: 10.1007/s10689-013-9661-8.
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation.
    • Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R.
    • Ann Intern Med. 2014 Feb 18;160(4):255-66.
    • Assessing the Genetic Risk for BRCA-Related Breast or Ovarian Cancer in Women: Recommendations From the U.S. Preventive Services Task Force.
    • [No authors listed]
    • Ann Intern Med. 2014 Feb 18;160(4). doi: 10.7326/P14-9008.

    Related:

    Systematic Review:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation.

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement.
    • Moyer VA; U.S. Preventive Services Task Force.
    • Ann Intern Med. 2014 Feb 18;160(4):271-81.

    Related:

    Patient Education Handout:

    Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.

    • Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
    • [No authors listed]
    • Ann Intern Med. 2014 Feb 18;160(4):I-16.

    Related:

    Practice Guideline:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement.

    • Risk management options elected by women after testing positive for a BRCA mutation.
    • Garcia C, Wendt J, Lyon L, Jones J, Littell RD, Armstrong MA, Raine-Bennett T, Powell CB.
    • Gynecol Oncol. 2014 Feb;132(2):428-33. doi: 10.1016/j.ygyno.2013.12.014. Epub 2013 Dec 16.
    • The 2013 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: MRI in breast cancer: where are we now?
    • McLaughlin S, Mittendorf EA, Bleicher RJ, McCready DR, King TA.
    • Ann Surg Oncol. 2014 Jan;21(1):28-36. doi: 10.1245/s10434-013-3307-9. Epub 2013 Oct 22.
    • Conference Report, Review
    • BRCA1 and BRCA2 - update and implications on the genetics of breast cancer: a clinical perspective.
    • Foulkes W.
    • Clin Genet. 2014 Jan;85(1):1-4. doi: 10.1111/cge.12291. Epub 2013 Oct 25.
    • Editorial / Commentary
    • Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria.
    • Singer C, Muhr D, Rappaport C, Tea MK, Gschwantler-Kaulich D, Fink-Retter A, Pfeiler G, Berger A, Sun P, Narod S.
    • Clin Genet. 2014 Jan;85(1):72-5. doi: 10.1111/cge.12216. Epub 2013 Jul 16.
    • The impact of bilateral salpingo-oophorectomy on breast MRI background parenchymal enhancement and fibroglandular tissue.
    • Price ER, Brooks JD, Watson EJ, Brennan SB, Comen EA, Morris EA.
    • Eur Radiol. 2014 Jan;24(1):162-8. doi: 10.1007/s00330-013-2993-9. Epub 2013 Aug 28.
    • Rapid increase in breast magnetic resonance imaging use: trends from 2000 to 2011.
    • Stout NK, Nekhlyudov L, Li L, Malin ES, Ross-Degnan D, Buist DS, Rosenberg MA, Alfisher M, Fletcher SW.
    • JAMA Intern Med. 2014 Jan;174(1):114-21. doi: 10.1001/jamainternmed.2013.11958.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG:

    Subject: percentage of women needing MRI

    • Patterns of breast magnetic resonance imaging use: an opportunity for data-driven resource allocation.
    • Hwang ES, Bedrosian I.
    • JAMA Intern Med. 2014 Jan;174(1):122-4. doi: 10.1001/jamainternmed.2013.10502.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG:

    Subject: percentage of women needing MRI

    Rapid increase in breast magnetic resonance imaging use: trends from 2000 to 2011.

    Patterns of breast magnetic resonance imaging use in community practice.

    Comment, Letters:

    In Defense of Screening for Breast Cancer With Magnetic Resonance Imaging.

    • Patterns of breast magnetic resonance imaging use in community practice.
    • Wernli KJ, DeMartini WB, Ichikawa L, Lehman CD, Onega T, Kerlikowske K, Henderson LM, Geller BM, Hofmann M, Yankaskas BC; Breast Cancer Surveillance Consortium.
    • JAMA Intern Med. 2014 Jan;174(1):125-32. doi: 10.1001/jamainternmed.2013.11963.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG:

    Subject: percentage of women needing MRI

    Comment:

    Patterns of breast magnetic resonance imaging use: an opportunity for data-driven resource allocation.

    • MRI Use Common, But Not Always Evidence-Based.
    • Kate O’Rourke.
    • Clinical Oncology. Vol. 08:12. 2013 Dec.
    • Do breast cancer risk factors differ among those who do and do not undertake mammography screening?
    • Beckmann KR, Roder DM, Hiller JE, Farshid G, Lynch JW.
    • J Med Screen. 2013 Dec;20(4):208-19. doi: 10.1177/0969141313510293. Epub 2013 Oct 23.
    • Is there a role for routine screening MRI in women with LCIS?
    • King TA, Muhsen S, Patil S, Koslow S, Oskar S, Park A, Morrogh M, Sakr RA, Morrow M.
    • Breast Cancer Res Treat. 2013 Nov;142(2):445-53. doi: 10.1007/s10549-013-2725-5. Epub 2013 Oct 19.
    • Ex vivo MRI evaluation of breast tumors: a novel tool for verifying resection of nonpalpable only MRI detected lesions.
    • Agresti R, Trecate G, Ferraris C, Valeri B, Maugeri I, Pellitteri C, Martelli G, Migliavacca S, Carcangiu ML, Bohm S, Maffioli L, Vergnaghi D, Panizza P.
    • Breast J. 2013 Nov;19(6):659-63. doi: 10.1111/tbj.12183. Epub 2013 Sep 19.
    • JOURNAL CLUB: Is screening MRI indicated for women with a personal history of breast cancer? Analysis based on biopsy results.
    • Arazi-Kleinman T, Skair-Levy M, Slonimsky E, Maly B, Uziely B, Libson E, Sella T.
    • AJR Am J Roentgenol. 2013 Oct;201(4):919-27. doi: 10.2214/AJR.11.8450.
    • Assessing the breast cancer risk distribution for women undergoing screening in British Columbia.
    • Weisstock CR, Rajapakshe R, Bitgood C, McAvoy S, Gordon PB, Coldman AJ, Parker BA, Wilson C.
    • Cancer Prev Res (Phila). 2013 Oct;6(10):1084-92. doi: 10.1158/1940-6207.CAPR-13-0027. Epub 2013 Aug 20.
    • Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
    • Saadatmand S1, Tilanus-Linthorst MM, Rutgers EJ, Hoogerbrugge N, Oosterwijk JC, Tollenaar RA, Hooning M, Loo CE, Obdeijn IM, Heijnsdijk EA, de Koning HJ.
    • J Natl Cancer Inst. 2013 Sep 4;105(17):1314-21. doi: 10.1093/jnci/djt203. Epub 2013 Aug 12.
    • Breast cancer size estimation with MRI in BRCA mutation carriers and other high risk patients.
    • Mann RM, Bult P, van Laarhoven HW, Span PN, Schlooz M, Veltman J, Hoogerbrugge N.
    • Eur J Radiol. 2013 Sep;82(9):1416-22. doi: 10.1016/j.ejrad.2013.03.003. Epub 2013 Apr 6.

    Related:

    Letter, Comment:

    Comparability versus statistical correctness.

    Letter, Comment:

    Good correlation does not automatically imply good agreement: the trouble with comparing tumour size by breast MRI versus histopathology.

    • Association between BRCA Mutation Status, Pathological Findings, and Magnetic Resonance Imaging Features in Patients with Breast Cancer at Risk for the Mutation.
    • Noh JM, Han BK, Choi DH, Rhee SJ, Cho EY, Huh SJ, Park W, Park H, Nam SJ, Lee JE, Kil WH.
    • J Breast Cancer. 2013 Sep;16(3):308-14. doi: 10.4048/jbc.2013.16.3.308. Epub 2013 Sep 30.
    • Accuracy of Self-Reported Screening Mammography Use: Examining Recall among Female Relatives from the Ontario Site of the Breast Cancer Family Registry.
    • Walker MJ, Chiarelli AM, Mirea L, Glendon G, Ritvo P, Andrulis IL, Knight JA.
    • ISRN Oncol. 2013 Aug 1;2013:810573. doi: 10.1155/2013/810573. eCollection 2013.
    • Perceived risk and adherence to breast cancer screening guidelines among women with a familial history of breast cancer: a review of the literature.
    • Walker MJ, Chiarelli AM, Knight JA, Mirea L, Glendon G, Ritvo P.
    • Breast. 2013 Aug;22(4):395-404. doi: 10.1016/j.breast.2012.12.005. Epub 2013 Jan 10.
    • Review
    • Exposure to diagnostic levels of radiation prior to age 30 increases the risk of breast cancer in BRCA1/2 carriers.
    • Haffty BG, Lee C.
    • Evid Based Med. 2013 Aug;18(4):e40. doi: 10.1136/eb-2012-101075. Epub 2012 Dec 5.
    • Comment

    Related:

    Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK).

    • Five-year analysis of magnetic resonance imaging as a screening tool in women at hereditary risk of breast cancer.
    • Kam JK, Naidu P, Rose AK, Mann GB.
    • J Med Imaging Radiat Oncol. 2013 Aug;57(4):400-6. doi: 10.1111/1754-9485.12030. Epub 2013 Jan 14.
    • Screening MR imaging versus screening ultrasound: pros and cons.
    • Mahoney MC, Newell MS.
    • Magn Reson Imaging Clin N Am. 2013 Aug;21(3):495-508. doi: 10.1016/j.mric.2013.04.001. Epub 2013 Jun 3.
    • Breast magnetic resonance imaging for screening high-risk women.
    • Sung JS, Dershaw DD.
    • Magn Reson Imaging Clin N Am. 2013 Aug;21(3):509-17. doi: 10.1016/j.mric.2013.02.006. Epub 2013 Apr 10.
    • Review
    • Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.
    • Pataky R, Armstrong L, Chia S, Coldman AJ, Kim-Sing C, McGillivray B, Scott J, Wilson CM, Peacock S.
    • BMC Cancer. 2013 Jul 10;13:339. doi: 10.1186/1471-2407-13-339.
    • Individually tailored screening of breast cancer with genes, tumour phenotypes, clinical attributes, and conventional risk factors.
    • Wu YY, Yen MF, Yu CP, Chen HH.
    • Br J Cancer. 2013 Jun 11;108(11):2241-9. doi: 10.1038/bjc.2013.202. Epub 2013 May 14.
    • Breast imaging in the young: the role of magnetic resonance imaging in breast cancer screening, diagnosis and follow-up.
    • Salem DS, Kamal RM, Mansour SM, Salah LA, Wessam R.
    • J Thorac Dis. 2013 Jun;5(Suppl 1):S9-S18. doi: 10.3978/j.issn.2072-1439.2013.05.02.
    • Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.
    • Møller P, Stormorken A, Jonsrud C, Holmen MM, Hagen AI, Clark N, Vabø A, Sun P, Narod SA, Mæhle L.
    • Breast Cancer Res Treat. 2013 May;139(1):155-61. doi: 10.1007/s10549-013-2540-z. Epub 2013 Apr 25.
    • Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness.
    • de Bock GH, Vermeulen KM, Jansen L, Oosterwijk JC, Siesling S, Dorrius MD, Feenstra T, Houssami N, Greuter MJ.
    • Br J Cancer. 2013 Apr 30;108(8):1579-86. doi: 10.1038/bjc.2013.149. Epub 2013 Apr 11.
    • Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
    • Cott Chubiz JE, Lee JM, Gilmore ME, Kong CY, Lowry KP, Halpern EF, McMahon PM, Ryan PD, Gazelle GS.
    • Cancer. 2013 Mar 15;119(6):1266-76. doi: 10.1002/cncr.27864. Epub 2012 Nov 26.
    • Evaluation of mammographic surveillance services in women aged 40-49 years with a moderate family history of breast cancer: a single-arm cohort study.
    • Duffy S, Mackay J, Thomas S, Anderson E, Chen T, Ellis I, Evans G, Fielder H, Fox R, Gui G, Macmillan D, Moss S, Rogers C, Sibbering M, Wallis M, Warren R, Watson E, Whynes D, Allgood P, Caunt J.
    • Health Technol Assess. 2013 Mar;17(11):1-95. doi: 10.3310/hta17110.
    • Breast cancer screening update.
    • Tria Tirona M.
    • Am Fam Physician. 2013 Feb 15;87(4):274-8.
    • Magnetic resonance imaging: value of diffusion-weighted imaging in differentiating benign from malignant breast lesions.
    • Stijven S, Gielen E, Bevernage C, Horvath M, Meylaerts L.
    • Eur J Obstet Gynecol Reprod Biol. 2013 Feb;166(2):215-20. doi: 10.1016/j.ejogrb.2012.10.029. Epub 2012 Dec 7.
    • Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing.
    • Mannis GN, Fehniger JE, Creasman JS, Jacoby VL, Beattie MS.
    • JAMA Intern Med. 2013 Jan 28;173(2):96-103. doi: 10.1001/2013.jamainternmed.962.

    Related:

    Comment:

    Role of genetic testing for screening and prevention for ovarian cancer: comment on "Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing".

    • Role of genetic testing for screening and prevention for ovarian cancer: comment on "Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing".
    • Grann V, Ashby-Thompson M.
    • JAMA Intern Med. 2013 Jan 28;173(2):103-4. doi: 10.1001/jamainternmed.2013.2729.

    Related:

    Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing.

    • NICE launches consultation on familial breast cancer guidelines.
    • Simon Leese.
    • PHG Foundation. 2013 Jan 15.
    • Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.
    • Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, Hadwin R, Cafferty FH, Benjamin E, Singh N, Evans DG, Eccles DM, Skates SJ, Mackay J, Menon U, Jacobs IJ.
    • J Clin Oncol. 2013 Jan 1;31(1):49-57. doi: 10.1200/JCO.2011.39.7638. Epub 2012 Dec 3.

    Related:

    Editorial:

    Screening for familial ovarian cancer: a ray of hope and a light to steer by.

    • Which Risk Model to Use? Clinical Implications of the ACS MRI Screening Guidelines.
    • Ozanne EM, Drohan B, Bosinoff P, Semine A, Jellinek M, Cronin C, Millham F, Dowd D, Rourke T, Block C, Hughes KS.
    • Cancer Epidemiol Biomarkers Prev. 2013 Jan;22(1):146-9. doi: 10.1158/1055-9965.EPI-12-0570. Epub 2012 Oct 23.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG:

    Subject: Breast cancer risk models

    Subject: Tyrer-Cuzick model

    Subject: Percent of women "high-risk" for breast cancer

    • Breast MRI Use Uncommon among U.S. Women.
    • Miller JW, Sabatino SA, Thompson TD, Breen N, White MC, Ryerson AB, Taplin S, Ballard-Barbash R.
    • Cancer Epidemiol Biomarkers Prev. 2013 Jan;22(1):159-66. doi: 10.1158/1055-9965.EPI-12-0967. Epub 2012 Nov 15.
    • ACR Appropriateness Criteria Breast Cancer Screening.
    • Mainiero MB, Lourenco A, Mahoney MC, Newell MS, Bailey L, Barke LD, D'Orsi C, Harvey JA, Hayes MK, Huynh PT, Jokich PM, Lee SJ, Lehman CD, Mankoff DA, Nepute JA, Patel SB, Reynolds HE, Sutherland ML, Haffty BG.
    • J Am Coll Radiol. 2013 Jan;10(1):11-4. doi: 10.1016/j.jacr.2012.09.036.
    • Review
    • Compliance with screening recommendations according to breast cancer risk levels in Izmir, Turkey.
    • Acikgoz A, Ergor G.
    • Asian Pac J Cancer Prev. 2013;14(3):1737-42.
    • [Choices for women at risk of hereditary breast cancer].
    • Saadatmand S, Obdeijn IM, Koppert LB, Tilanus-Linthorst M.
    • Ned Tijdschr Geneeskd. 2013;157(43):A6625.
    • Case report, Review, [Article in Dutch]
    • Accuracy and value of breast ultrasound for primary imaging evaluation of symptomatic women 30-39 years of age.
    • Lehman CD, Lee CI, Loving VA, Portillo MS, Peacock S, DeMartini WB.
    • AJR Am J Roentgenol. 2012 Nov;199(5):1169-77. doi: 10.2214/AJR.12.8842.
    • Chromosomal instability induced by mammography X-rays in primary human fibroblasts from BRCA1 and BRCA2 mutation carriers.
    • Frankenberg-Schwager M, Gregus A.
    • Int J Radiat Biol. 2012 Nov;88(11):846-57. doi: 10.3109/09553002.2012.711500. Epub 2012 Oct 1.
    • Breast cancer: Radiation risk in BRCA carriers.
    • Hutchinson L.
    • Nat Rev Clin Oncol. 2012 Nov;9(11):611. doi: 10.1038/nrclinonc.2012.175. Epub 2012 Sep 25.
    • Comment

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Article Request

    Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK).

    • Anxiety and specific distress in women at intermediate and high risk of breast cancer before and after surveillance by magnetic resonance imaging and mammography versus standard mammography.
    • Brédart A, Kop JL, Fall M, Pelissier S, Simondi C, Dolbeault S, Livartowski A, Tardivon A; Magnetic Resonance Imaging study group (STIC IRM 2005).
    • Psychooncology. 2012 Nov;21(11):1185-94. doi: 10.1002/pon.2025. Epub 2011 Aug 3.
    • Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years.
    • Wu LC, Grabaud BI, Gail MH.
    • Ann Intern Med. 2012 Oct 16;157(8):597. doi: 10.7326/0003-4819-157-8-201210160-00019.
    • Letter, Comment

    Related:

    Clinical Guidelines:

    Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement.

    • Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial.
    • Saadatmand S, Rutgers EJ, Tollenaar RA, Zonderland HM, Ausems MG, Keymeulen KB, Schlooz-Vries MS, Koppert LB, Heijnsdijk EA, Seynaeve C, Verhoef C, Oosterwijk JC, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MM.
    • BMC Cancer. 2012 Oct 2;12:440. doi: 10.1186/1471-2407-12-440.
    • Computerized analysis of mammographic parenchymal patterns on a large clinical dataset of full-field digital mammograms: robustness study with two high-risk datasets.
    • Li H, Giger ML, Lan L, Bancroft Brown J, MacMahon A, Mussman M, Olopade OI, Sennett C.
    • J Digit Imaging. 2012 Oct;25(5):591-8.
    • Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK).
    • Pijpe A, Andrieu N, Easton DF, Kesminiene A, Cardis E, Noguès C, Gauthier-Villars M, Lasset C, Fricker JP, Peock S, Frost D, Evans DG, Eeles RA, Paterson J, Manders P, van Asperen CJ, Ausems MG, Meijers-Heijboer H, Thierry-Chef I, Hauptmann M, Goldgar D, Rookus MA, van Leeuwen FE; GENEPSO; EMBRACE; HEBON.
    • BMJ. 2012 Sep 6;345:e5660. doi: 10.1136/bmj.e5660.

    Related:

    Comment:

    Exposure to diagnostic levels of radiation prior to age 30 increases the risk of breast cancer in BRCA1/2 carriers.

    Comment:

    Breast cancer: Radiation risk in BRCA carriers.

    Research News:

    X-rays increase breast cancer risk in women with gene mutation.

    Press: X-Rays May Up Breast Cancer Risk for Women With Certain Genes: Study (HealthDay)

    • Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.
    • Heijnsdijk EA, Warner E, Gilbert FJ, Tilanus-Linthorst MM, Evans G, Causer PA, Eeles RA, Kaas R, Draisma G, Ramsay EA, Warren RM, Hill KA, Hoogerbrugge N, Wasser MN, Bergers E, Oosterwijk JC, Hooning MJ, Rutgers EJ, Klijn JG, Plewes DB, Leach MO, de Koning HJ.
    • Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1458-68. doi: 10.1158/1055-9965.EPI-11-1196. Epub 2012 Jun 28.
    • Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients.
    • Chung A, Huynh K, Lawrence C, Sim MS, Giuliano A.
    • Ann Surg Oncol. 2012 Aug;19(8):2600-6. doi: 10.1245/s10434-012-2299-1. Epub 2012 Mar 7.
    • Supplementary imaging for breast cancer screening in high-risk women.
    • Narod SA.
    • JAMA. 2012 Jul 18;308(3):236; author reply 236-7. doi: 10.1001/jama.2012.7547.
    • Comment, Letter

    Related:

    Comment, Letter:

    Supplementary imaging for breast cancer screening in high-risk women.

    Letter: Supplementary Imaging for Breast Cancer Screening in High-Risk Women—Reply. (JAMA)

    • Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: further evidence of benefit.
    • Maurice A, Evans DG, Affen J, Greenhalgh R, Duffy SW, Howell A.
    • Int J Cancer. 2012 Jul 15;131(2):417-25. doi: 10.1002/ijc.26394. Epub 2011 Oct 20.
    • Long-term results of screening with magnetic resonance imaging in women with BRCA mutations.
    • Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW, Jong RA, Wright FC, Yaffe MJ, Ramsay EA, Balasingham S, Verity L, Eisen A, Curpen B, Shumak R, Plewes DB, Narod SA.
    • Br J Cancer. 2012 Jun 26;107(1):24-30. doi: 10.1038/bjc.2012.204. Epub 2012 May 15.
    • Managing the breast in patients who test positive for hereditary breast cancer.
    • Euhus D.
    • Ann Surg Oncol. 2012 Jun;19(6):1738-44. doi: 10.1245/s10434-012-2258-x. Epub 2012 Mar 7.
    • Review
    • Implementation and outcomes of a multidisciplinary high-risk breast cancer program: the William Beaumont Hospital experience.
    • Shah C, Berry S, Dekhne N, Lanni T, Lowry H, Vicini F.
    • Clin Breast Cancer. 2012 Jun;12(3):215-8. doi: 10.1016/j.clbc.2012.03.002. Epub 2012 Apr 14.
    • Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk.
    • van Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, Buist DS, Huang H, Heijnsdijk EA, Trentham-Dietz A, Alagoz O, Near AM, Kerlikowske K, Nelson HD, Mandelblatt JS, de Koning HJ.
    • Ann Intern Med. 2012 May 1;156(9):609-17. doi: 10.7326/0003-4819-156-9-201205010-00002.

    Related:

    Comment, Editorial:

    Risk-based mammography screening: an effort to maximize the benefits and minimize the harms.

    News:

    Studies support risk-based mammography screening.

    • Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis.
    • Lowry KP, Lee JM, Kong CY, McMahon PM, Gilmore ME, Cott Chubiz JE, Pisano ED, Gatsonis C, Ryan PD, Ozanne EM, Gazelle GS.
    • Cancer. 2012 Apr 15;118(8):2021-30. doi: 10.1002/cncr.26424. Epub 2011 Sep 20.

    Related:

    Press: Early Breast Cancer Screening May Help Some With Mutations. (Medscape)

    • Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk.
    • Berg WA, Zhang Z, Lehrer D, Jong RA, Pisano ED, Barr RG, Böhm-Vélez M, Mahoney MC, Evans WP 3rd, Larsen LH, Morton MJ, Mendelson EB, Farria DM, Cormack JB, Marques HS, Adams A, Yeh NM, Gabrielli G; ACRIN 6666 Investigators.
    • JAMA. 2012 Apr 4;307(13):1394-404. doi: 10.1001/jama.2012.388.

    Related:

    Letter, Comment:

    Supplementary imaging for breast cancer screening in high-risk women.

    Letter, Comment:

    Supplementary imaging for breast cancer screening in high-risk women.

    Comment:

    The challenge of individualizing treatments for patients with breast cancer.

    • Follow-up frequency and compliance in women with probably benign findings on breast magnetic resonance imaging.
    • Marshall AL, Domchek SM, Weinstein SP.
    • Acad Radiol. 2012 Apr;19(4):406-11. Epub 2012 Jan 9.
    • Self-reported mammography use following BRCA1/2 genetic testing may be overestimated.
    • Larouche G, Bouchard K, Chiquette J, Desbiens C, Simard J, Dorval M.
    • Fam Cancer. 2012 Mar;11(1):27-32. doi: 10.1007/s10689-011-9490-6.
    • High-Risk Surveillance for Breast Cancer.
    • Christopher Flowers.
    • FORCE. Be Empowered Webinars. 2012 Feb 22.
    • Online tool to guide decisions for BRCA1/2 mutation carriers.
    • Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK.
    • J Clin Oncol. 2012 Feb 10;30(5):497-506. doi: 10.1200/JCO.2011.38.6060. Epub 2012 Jan 9.

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: An Online BRCA Positive Decision Guidance Tool.

    Comment:

    Are we ready for online tools in decision making for BRCA1/2 mutation carriers?

    Press: Are We Ready for Online Tools in Decision Making for BRCA1/2 Mutation Carriers? (Journal of Clinical Oncology)

    Press: Online tool helps those with BRCA mutations understand options. (Medical Xpress)

    • The influence of preoperative MRI on breast cancer treatment.
    • Miller BT, Abbott AM, Tuttle TM.
    • Ann Surg Oncol. 2012 Feb;19(2):536-40. doi: 10.1245/s10434-011-1932-8. Epub 2011 Jul 13.
    • Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.
    • Schwartz MD, Isaacs C, Graves KD, Poggi E, Peshkin BN, Gell C, Finch C, Kelly S, Taylor KL, Perley L.
    • Cancer. 2012 Jan 15;118(2):510-7. doi: 10.1002/cncr.26294. Epub 2011 Jun 29.
    • Screening mammography in men with BRCA mutations: is there a role?
    • Freedman BC, Keto J, Rosenbaum Smith SM.
    • Breast J. 2012 Jan-Feb;18(1):73-5. doi: 10.1111/j.1524-4741.2011.01185.x.
    • Case Report
    • Breast cancer risk assessment in 64,659 women at a single high-volume mammography clinic.
    • Brinton JT, Barke LD, Freivogel ME, Jackson S, O'Donnell CI, Glueck DH.
    • Acad Radiol. 2012 Jan;19(1):95-9. doi: 10.1016/j.acra.2011.09.003. Epub 2011 Nov 3.
    • Effect of protocol-related variables and women's characteristics on the cumulative false-positive risk in breast cancer screening.
    • Román R, Sala M, Salas D, Ascunce N, Zubizarreta R, Castells X.
    • Ann Oncol. 2012 Jan;23(1):104-111. doi: 10.1093/annonc/mdr032. Epub 2019 Dec 4.